A Phase 2 interventional study of GSK2894512 1% Cream and GSK2894512 0.5% Cream in Dermatitis, Atopic, sponsored by GlaxoSmithKline. Completed at 60 sites in 3 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-11-20.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing tapinarof in Dermatitis, Atopic — 1 open to participants now, 2 under way, 1 of them phase 3. tapinarof · Dermatitis, Atopic.
Among the 12 studies testing tapinarof in Dermatitis, Atopic, this one is the 4th largest by enrollment, is one of 3 that started in 2015, is one of 3 in phase 2, and was the 5th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →1 of the 12 studies testing tapinarof in Dermatitis, Atopic is open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
tapinarof: first FDA approval 2022 (VTAMA). What it is approved for, and how studies give it, is on its page →
Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 12 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 5 · Phase 4 1
First in 2008; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 247 is above the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 168 across the 12 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 12 have an industry lead sponsor. The 5 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
19 studies in Dermatitis, Atopic by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 19 finished, 7 (37%) have results posted.
Among the 19 studies in Dermatitis, Atopic by GlaxoSmithKline, this one is the 2nd largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2015, is one of 8 in phase 2, and was the 11th registered.
GlaxoSmithKline’s Dermatitis, Atopic studies by the year they started, since 2005.
1 of the studies testing tapinarof in Dermatitis, Atopic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07265479Phase 3Organon and CoA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing tapinarof in Dermatitis, Atopic, from their registry updates:
Among GlaxoSmithKline’s 19 in Dermatitis, Atopic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of two concentrations (0.5 percent [%] and 1%) and two application frequencies (once a day and twice a day) of GSK2894512 cream for the topical treatment in adolescent and adult subjects with atopic dermatitis. Results from this study will be considered when selecting the most appropriate concentration of GSK2894512 cream and application frequency in future clinical studies. This is a multicenter (United States, Canada, and Japan), randomized, double-blind (sponsor-unblind), vehicle-controlled, 6-arm, parallel-group, dose-finding study in adolescent and adult subjects with atopic dermatitis. Two concentrations of GSK2894512 cream (0.5% and 1%) and a vehicle control cream will be equally randomized and evaluated following application to all atopic dermatitis lesions (except on the scalp) once daily (evening) or twice daily (morning and evening) for 12 weeks. This study will consist of 3 periods: up to 4 weeks screening, 12 weeks double-blind treatment, and 4 weeks post-treatment follow-up. The total duration of subject participation will be approximately 16 to 20 weeks. Approximately 270 adolescent and adult males and females subjects with atopic dermatitis will be screened in order to have at least 228 randomized subjects (38 subjects for each of the 6 treatment groups) and approximately 204 evaluable subjects overall. Approximately 30 subjects will be randomized in Japan to achieve at least 24 evaluable Japanese subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
NOTES: The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF), with machine over-read. The QTc should be based on a single obtained over a brief recording period. If QTc is outside of the threshold value, triplicate ECGs may be performed with the QTc values averaged.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will apply a thin layer of GSK2894512 1% (10 milligram per gram \[mg/g\]) topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
Drug: GSK2894512 1% Cream
Subjects will apply a thin layer of GSK2894512 1% (10 mg/g) topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
Drug: GSK2894512 1% Cream
Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
Drug: GSK2894512 0.5% Cream
Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
Drug: GSK2894512 0.5% Cream
Subjects will apply a thin layer of vehicle topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
Drug: Vehicle cream
Subjects will apply a thin layer of vehicle topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
Drug: Vehicle cream
1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
White to off-white vehicle cream base to be applied topically
Percentage of Participants Who Have an Investigator Global Assessment (IGA) Score of Clear or Almost Clear (0 or 1) at Week 12 and a Minimum 2 Grade Improvement in IGA Score From Baseline to Week 12 for Intent to Treat (ITT) Population
The IGA is a clinical tool for assessing the current state/severity of a participant's AD. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines. The percentage of participants who have an IGA score of clear or almost clear at Week 12 and a minimum 2 grade improvement from Baseline to Week 12 in IGA score was presented. . The analysis was performed on ITT Population which comprised of all randomized participants.
Time frame: Baseline and up to Week 12
Mean Change From Baseline in Weekly Average of Daily Itch/Pruritus (Numeric Rating Scale [NRS]) Score
NRS is a 11-point tool ranging from 0 (absent) to 10 (worst imaginable) to assess the severity of 11 disease-related signs and symptoms including itching, discoloration, bleeding, oozing, cracking, scaling, flaking, dry/rough, painful, burning, and stinging. Participants were asked to complete the self-administered sign and symptom severity diary containing NRS using a recall period of the past 24 hours. Question 1 of the diary was used to assess itch. Mean change from Baseline to Week 12 in weekly average of daily itch/pruritus based on the NRS was presented using mean and standard deviation (SD). Baseline was defined as the latest assessment prior to first dose and Change from Baseline was defined as post-dose weekly average value minus Baseline value.
Time frame: Baseline and up to Week 12
Mean Percent Change From Baseline in Weekly Average of Daily Itch/Pruritus NRS Score
NRS is a 11-point tool ranging from 0 (absent) to 10 (worst imaginable) to assess the severity of 11 disease-related signs and symptoms including itching, discoloration, bleeding, oozing, cracking, scaling, flaking, dry/rough, painful, burning, and stinging. Participants were asked to complete the self-administered sign and symptom severity diary containing NRS using a recall period of the past 24 hours. Question 1 of the diary was used to assess itch. Mean percent change in weekly average of daily itch/pruritus based on the NRS was presented using mean and SD from Baseline to Week 12. Baseline was defined as the latest assessment prior to first dose and Change from Baseline was defined as post-dose weekly average value minus Baseline value.
Time frame: Baseline and up to Week 12
Percentage of Participants Who Achieve a Minimum 3- Point Improvement in Itch/Pruritus (NRS) From Baseline to Each Study Visit
NRS is a 11-point tool ranging from 0 (absent) to 10 (worst imaginable) to assess the severity of 11 disease-related signs and symptoms including itching, discoloration, bleeding, oozing, cracking, scaling, flaking, dry/rough, painful, burning, and stinging. Participants were asked to complete the self-administered sign and symptom severity diary containing NRS using a recall period of the past 24 hours. Question 1 of the diary was used to assess itch. Percentage of participants who achieved a minimum 3-point improvement in itch/pruritus (NRS) from Baseline to each study visit were measured. Baseline was defined as the latest assessment prior to first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Time frame: Week 1, 2, 4, 8, 12, 14, 16, early withdrawal (EW) (up to Week 16)
Mean Change From Baseline in Eczema Area and Severity Index (EASI) Score
The EASI scoring system is a standard clinical tool for assessing the severity of AD that takes into account the overall severity of erythema, infiltration/papulation, excoriation, and lichenification, as well as the extent of BSA affected with AD. These 4 clinical signs were graded on a 4-point scale (0 \[absent\] to 3 \[severe\]) for each of the 4 specified body regions (head and neck, upper extremities, lower extremities, and trunk). Body area involvement ranged from 0 (0%) to 6 (90-100%). Total EASI score was calculated as a sum of scores of all 4 specified body region. Range for EASI total score is 0 (absent) to 72 (severe). Baseline was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Mean change from Baseline was presented in the form of mean and SD. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Week 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Mean Percent Change From Baseline in EASI Score
The EASI scoring system is a standard clinical tool for assessing the severity of AD that takes into account the overall severity of erythema, infiltration/papulation, excoriation, and lichenification, as well as the extent of BSA affected with AD. These 4 clinical signs were graded on a 4-point scale (0 \[absent\] to 3 \[severe\]) for each of the 4 specified body regions (head and neck, upper extremities, lower extremities, and trunk). Body area involvement ranged from 0 (0%) to 6 (90-100%). Total EASI score was calculated as a sum of scores of all 4 specified body region. Range for EASI total score is 0 (absent) to 72 (severe). Baseline was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Mean percent change from Baseline was presented in the form of mean and SD. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Percentage of Participants With a Minimum 2-grade Improvement in IGA Score From Baseline to Each Visit
The IGA is a clinical tool for assessing the current state/severity of a participant's AD. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines. IGA is made without reference to previous scores. The percentage of participants with a minimum 2-grade improvement in IGA score from Baseline at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and early withdrawal (EW) visit was presented in the form of mean and SD. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Percentage of Participants With an IGA Score of 0 or 1 at Each Visit
The IGA is a clinical tool for assessing the current state/severity of a participant's AD. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines. IGA is made without reference to previous scores. The percentage of participants with an IGA score of 0 or 1 at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW visit was presented in the form of mean and SD. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Percentage of Participants With >=50 Percent Improvement From Baseline in EASI
The EASI scoring system is a standard clinical tool for assessing the severity of AD that takes into account the overall severity of erythema, infiltration/papulation, excoriation, and lichenification, as well as the extent of BSA affected with AD. These 4 clinical signs were graded on a 4-point scale for each of the 4 specified body regions (head and neck, upper extremities, lower extremities, and trunk). Percentage of participants with \>=50 percent improvement in EASI score from Baseline to Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW were presented and statistical analysis was performed using a repeated measures factorial logistic regression model. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Percentage of Participants With >=75 Percent Improvement From Baseline in EASI
The EASI scoring system is a standard clinical tool for assessing the severity of AD that takes into account the overall severity of erythema, infiltration/papulation, excoriation, and lichenification, as well as the extent of BSA affected with AD. These 4 clinical signs were graded on a 4-point scale for each of the 4 specified body regions (head and neck, upper extremities, lower extremities, and trunk). Percentage of participants with \>=75 percent improvement in EASI score from Baseline to Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW were presented and statistical analysis was performed using a repeated measures factorial logistic regression model. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Mean Change From Baseline in Total Severity Score (TSS)
A target lesion of at least 3 centimeter square (cm\^2) was selected at Baseline. The severity of the following signs: erythema, induration/papulation, lichenification, oozing/crusting, and scaling was assessed on a 4-point scale ranging from 0 (absent) to 3 (severe), with higher values indicating greater severity of symptoms. TSS (maximum score 15) was calculated based on these signs. Mean change from Baseline in TSS at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW visit was presented using mean and SD. Baseline value was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Mean Percent Change From Baseline in TSS
A target lesion of at least 3 cm\^2 was selected at Baseline. The severity of the following signs: erythema, induration/papulation, lichenification, oozing/crusting, and scaling was assessed on a 4-point scale ranging from 0 (absent) to 3 (severe) , with higher values indicating greater severity of symptoms. TSS (maximum score 15) was calculated based on these signs. Mean percent change from Baseline in TSS at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW visit was presented using mean and SD. Baseline value was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Week 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Mean Change From Baseline in Individual Signs of TSS
The severity of the following signs: erythema, induration/papulation, lichenification, oozing/crusting, and scaling was assessed on a 4-point scale ranging from 0 (absent) to 3 (severe) and TSS (maximum score 15) was calculated based on these signs. Mean change from Baseline in individual signs of TSS was presented using mean and SD. Baseline value was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. If the participant had more than 3 missing days during the week, then the weekly average was not calculated and treated as missing data and excluded from the analysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Mean Percent Change From Baseline in Individual Signs of TSS
The severity of the following signs: erythema, induration/papulation, lichenification, oozing/crusting, and scaling was assessed on a 4-point scale ranging from 0 (absent) to 3 (severe) and TSS (maximum score 15) was calculated based on these signs. Mean percent change from Baseline in individual signs of TSS was presented using mean and SD. Baseline value was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. NA indicates that data were not available. If the participant had more than 3 missing days during the week, then the weekly average was not calculated and treated as missing data and excluded from the analysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Week 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Mean Change From Baseline in Body Surface Area (Percent BSA)
The extent of BSA affected by AD is a general indicator of disease severity and the assessment of BSA with AD was performed separately for four body surface regions: the head (h), the upper extremities (u), the trunk (t) and the lower extremities (l), corresponding to 10, 20, 30, and 40 percent of the total body area, respectively. Mean change from Baseline in percent BSA was presented using mean and SD at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW visit. Baseline was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Mean Change From Baseline in IGA Score
The IGA is a clinical tool for assessing the current state/severity of a participant's AD. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines. IGA is made without reference to previous scores. Score ranges from 0 (clear) to 4 (severe). Higher values represent a severe disease. Mean change from Baseline in IGA score was presented using mean and SD at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW visit. Baseline was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Percentage of Participants Who Have an IGA Score of Clear or Almost Clear (0 or 1) and a Minimum 2 Grade Improvement in IGA Score From Baseline to Each Study Visit
The IGA is a clinical tool for assessing the current state/severity of a participant's AD. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines. IGA is made without reference to previous scores. The percentage of participants who have an IGA score of clear or almost clear and a minimum 2 grade improvement from Baseline to each study visit in IGA score was presented. The statistical analysis was performed using a repeated measures factorial logistic regression model with covariates for dose, frequency of administration, and study day as well as a dose by frequency interaction term. The analysis was performed on ITT Population which comprised of all randomized participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category title).
Time frame: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to week 16)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth effect, other situations and is associated with liver injury or impaired liver function. Treatment emergent AEs (TEAE) is defined as AE occurred on or after study treatment start date and on or before last visit. Number of participants with AEs and serious TEAEs were presented. The analysis was performed on Safety population which comprised of all participants who receive at least one dose of study treatment.
Time frame: Weeks 1, 2, 4, 8, 12, 14, EW (up to week 14)
Number of Participants With Reported Tolerability Score of 0 to 4 Over Time
Participants were asked to use a 5-point tolerability scale from 0 (none) to 4 (severe) to assess the presence and degree of burning/stinging and itching at the application sites that has generally been experienced following application of the study treatment. The score represented an 'average' across all application sites. A score of 3 or 4 was reported as an AE. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Week 1, 2, 4, 8, 12, 14, EW (up to Week 14)
Change From Baseline in Albumin and Total Protein
Blood samples were collected to evaluate change from Baseline in albumin and total protein values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
Time frame: Week 1, 2, 4, 8, 12, 14, EW (up to week 14)
Change From Baseline in Alkaline Phosphatase (Alk.Phosph.), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Gamma Glutamyl Transferase (GGT)
Blood samples were collected to evaluate change from Baseline in Alk.phosph., ALT, AST and GGT values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
Time frame: Week 2, 4, 8, 12, 14, EW (up to week 14)
Change From Baseline in Direct and Total Bilirubin, Creatinine and Urate
Blood samples were collected to evaluate change from Baseline in direct and total bilirubin, creatinine and urate values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
Time frame: Week 2, 4, 8, 12, 14, EW (up to week 14)
Change From Baseline in Calcium, Chloride, Carbon Dioxide (CO2), Glucose, Potassium, Sodium, Blood Urea Nitrogen (BUN)
Blood samples were collected to evaluate change from Baseline in calcium, chloride, CO2, glucose, potassium, sodium and BUN values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
Time frame: Week 2, 4, 8, 12, 14, EW (up to week 14)
Number of Participants With Chemistry Data of Potential Clinical Importance
Blood samples were collected from participants for evaluation of clinical chemistry parameters by Potential Clinical Importance Criteria from Baseline to Week 14, EW and any visit post-screen. The vital signs included alk.phosph., ALT, AST, bilirubin, calcium, CO2, creatinine, glucose and potassium. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Time frame: Week 2, 4, 8, 12, 14, EW (up to week 14)
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet, Leukocytes Count
Blood samples were collected to evaluate change from Baseline in basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet and leukocytes and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
Time frame: Week 2, 4, 8, 12, 14, EW (up to week 14)
Change From Baseline in Hematocrit Levels
Blood samples were collected to evaluate change from Baseline in hematocrit and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
Time frame: Week 2, 4, 8, 12, 14, EW (up to week 14)
Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC)
Blood samples were collected to evaluate change from Baseline in hemoglobin and MCHC and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
Time frame: Week 2, 4, 8, 12, 14, EW (up to week 14)
Change From Baseline in Mean Corpuscle Hemoglobin (MCH)
Blood samples were collected to evaluate change from Baseline in MCH and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
Time frame: Week 2, 4, 8, 12, 14, EW (up to week 14)
Change From Baseline in Mean Corpuscle Volume (MCV)
Blood samples were collected to evaluate change from Baseline in MCV and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
Time frame: Week 2, 4, 8, 12, 14, EW (up to week 14)
Change From Baseline in Erythrocyte Count
Blood samples were collected to evaluate change from Baseline in erythrocytes and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
Time frame: Weeks 2, 4, 8, 12, 14, EW (week up to 14)
Number of Participants With Hematology Data of Potential Clinical Importance
Blood samples were collected from participants for evaluation of hematology parameters by Potential Clinical Importance Criteria from Baseline to Week 14, EW and any visit post-screen. The vital signs included hematocrit, hemoglobin, lymphocytes, neutrophils, platelet and leukocytes. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Time frame: Baseline, Week 2, 4, 8, 12, 14, early withdrawal, and post screen (up to Week 16)
Change From Baseline in Total T Lymphocytes (Lympho), B Lympho, Natural Killer (NK) Lymphocytes and Treg (Foxp3) Levels
Blood samples were collected to evaluate change from Baseline in total T lympho, B lympho, T and B NK cells and (Foxp3) values at Baseline throughout the 12 weeks of study treatment. The immunophenotyping parameters included cluster of differentiation (CD)19, CD3, CD3+CD8+, CD3+CD4+, CD16+CD56+, CD3+CD4+CD25+CD127, CD3+CD4+foxP3+CD25+CD127 and T and NK lympho. CD3, CD3+CD8+ and CD3+CD4+ were also evaluated by using treg flow cytometry (cyto). Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
Time frame: Week, 4, 8 and 12
Number of Participants With Immunopheotyping Data Outside the Reference Range
Blood samples were collected from participants for evaluation of immunophenotyping parameters by Potential Clinical Importance Criteria at Baseline, Week 4, Week 8, Week 12 nd any visit post-screen. The immunophenotyping parameters included CD 19, CD3, CD3+CD8+, CD3+CD4+, CD16+CD56+, CD3+CD4+CD25+CD127, CD3+CD4+foxP3+CD25+CD127 and T and NK lympho. CD3, CD3+CD8+ and CD3+CD4+ were also evaluated by using treg flow cyto. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Time frame: Baseline, Week, 4, 8, 12 and post-screen (up to Week 16)
Change From Baseline in Immunoglobin (Ig) A, IgG and IgM Levels
Blood samples were collected to evaluate change from Baseline in IgA, IgG, IM values at Baseline throughout the 12 weeks of study treatment. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
Time frame: Week, 4, 8 and 12
Number of Participants With Immunoglobulin Data Outside the Reference Range
Blood samples were collected from participants for evaluation of immunoglobulin data outside the reference range at Baseline, Week 4, Week 8, Week 12 and any visit post-screen. The immunoglobulin parameters included IgA, IgG and Ig M. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Time frame: Baseline, Week, 4, 8, 12, post-screen (up to Week 16)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
SBP and DBP were measured from Baseline up to follow up Visit 1 at Week 14 in semi-supine position after at least 5 minutes of rest. The Baseline value was taken at Day 1 and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
Time frame: Week 1, 2, 4, 8, 12, 14, EW (up to week 14)
Change From Baseline in Pulse Rate
Pulse rate were measured from Baseline up to follow up Visit 1 at Week 14 in semi-supine position after at least 5 minutes of rest. The Baseline value was taken at Day 1 and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
Time frame: Week 1, 2, 4, 8, 12, 14, EW (up to week 14)
Change From Baseline in Temperature
Temperature were measured from Baseline up to follow up Visit 1 at Week 14 in semi-supine position after at least 5 minutes of rest. The Baseline value was taken at Day 1 and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
Time frame: Week 1, 2, 4, 8, 12, 14, EW (up to week 14)
Number of Participants With Vital Signs of Potential Clinical Importance
Blood samples were collected from participants for evaluation of vital signs by Potential Clinical Importance Criteria from Baseline to Week 14, EW and any visit post-screen. The vital signs included SBP, DBP and pulse rate. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Time frame: Baseline, Week 2, 4, 8, 12, 14, EW (up to week 14)
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
Single measurements of 12-lead ECGs were obtained at Baseline , Week 1, Week 12, Week 14 (follow up 1), EW and at any time post-screen using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (QTc). Baseline was defined as the latest assessment prior to the first dose. For multiple ECGs at one visit, or "Any visit post-screen", a participant was categorized as "Abnormal" if \>=1 assessment was abnormal. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline, Week 1, 12, 14, EW ( up to Week 14), post-screen
Eligible participants entered a 4 weeks screening phase and participants who met the eligibility criteria entered into the 12 weeks double-blind treatment phase and 4 weeks post-treatment follow-up phase. The total duration of participation in the study was 16 to 20 weeks.
| Milestone | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Started | 40 | 41 | 43 | 41 | 42 | 40 |
| Completed | 34 | 36 | 31 | 35 | 27 | 28 |
| Not completed | 6 | 5 | 12 | 6 | 15 | 12 |
| Withdrew: Adverse event | 1 | 0 | 4 | 1 | 4 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Reached stopping criteria | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 4 | 2 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 4 | 3 | 3 | 10 | 10 |
The IGA is a clinical tool for assessing the current state/severity of a participant's AD. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines. The percentage of participants who have an IGA score of clear or almost clear at Week 12 and a minimum 2 grade improvement from Baseline to Week 12 in IGA score was presented. . The analysis was performed on ITT Population which comprised of all randomized participants.
| Percentage of participant | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Have an Investigator Global Assessment (IGA) Score of Clear or Almost Clear (0 or 1) at Week 12 and a Minimum 2 Grade Improvement in IGA Score From Baseline to Week 12 for Intent to Treat (ITT) Population | 58 | 51 | 50 | 40 | 36 | 44 |
NRS is a 11-point tool ranging from 0 (absent) to 10 (worst imaginable) to assess the severity of 11 disease-related signs and symptoms including itching, discoloration, bleeding, oozing, cracking, scaling, flaking, dry/rough, painful, burning, and stinging. Participants were asked to complete the self-administered sign and symptom severity diary containing NRS using a recall period of the past 24 hours. Question 1 of the diary was used to assess itch. Mean change from Baseline to Week 12 in weekly average of daily itch/pruritus based on the NRS was presented using mean and standard deviation (SD). Baseline was defined as the latest assessment prior to first dose and Change from Baseline was defined as post-dose weekly average value minus Baseline value.
| Scores on a scale | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Mean Change From Baseline in Weekly Average of Daily Itch/Pruritus (Numeric Rating Scale [NRS]) Score | -3.06 ± 2.657 | -3.10 ± 2.493 | -3.52 ± 2.307 | -3.39 ± 2.297 | -0.95 ± 2.107 | -3.50 ± 2.742 |
NRS is a 11-point tool ranging from 0 (absent) to 10 (worst imaginable) to assess the severity of 11 disease-related signs and symptoms including itching, discoloration, bleeding, oozing, cracking, scaling, flaking, dry/rough, painful, burning, and stinging. Participants were asked to complete the self-administered sign and symptom severity diary containing NRS using a recall period of the past 24 hours. Question 1 of the diary was used to assess itch. Mean percent change in weekly average of daily itch/pruritus based on the NRS was presented using mean and SD from Baseline to Week 12. Baseline was defined as the latest assessment prior to first dose and Change from Baseline was defined as post-dose weekly average value minus Baseline value.
| Percentage Change | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Mean Percent Change From Baseline in Weekly Average of Daily Itch/Pruritus NRS Score | -64.69 ± 36.916 | -58.34 ± 45.632 | -60.39 ± 44.314 | -61.40 ± 34.958 | -29.16 ± 55.251 | -55.62 ± 40.320 |
NRS is a 11-point tool ranging from 0 (absent) to 10 (worst imaginable) to assess the severity of 11 disease-related signs and symptoms including itching, discoloration, bleeding, oozing, cracking, scaling, flaking, dry/rough, painful, burning, and stinging. Participants were asked to complete the self-administered sign and symptom severity diary containing NRS using a recall period of the past 24 hours. Question 1 of the diary was used to assess itch. Percentage of participants who achieved a minimum 3-point improvement in itch/pruritus (NRS) from Baseline to each study visit were measured. Baseline was defined as the latest assessment prior to first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
| Percentage of Participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1; n= 29,35,33,31,24,25 | 24 | 9 | 9 | 16 | 8 | 12 |
| Week 2; n= 28,30,36,30,26,23 | 36 | 33 | 22 | 33 | 12 | 22 |
| Week 4; n= 31,31,29,31,20,25 | 42 | 48 | 45 | 52 | 35 | 28 |
| Week 8; n= 26,26,29,30,21,23 | 46 | 50 | 48 | 57 | 29 | 30 |
| Week 12; n= 22,25,23,23,14,16 | 55 | 52 | 61 | 52 | 14 | 38 |
| Week 14; n= 21,20,19,20,17,14 | 38 | 40 | 58 | 50 | 29 | 50 |
| Week 16; n= 15,14,22,17,12,13 | 33 | 21 | 41 | 47 | 17 | 23 |
| EW; n= 0,3,2,2,5,6 | — | 0 | 50 | 50 | 0 | 17 |
The EASI scoring system is a standard clinical tool for assessing the severity of AD that takes into account the overall severity of erythema, infiltration/papulation, excoriation, and lichenification, as well as the extent of BSA affected with AD. These 4 clinical signs were graded on a 4-point scale (0 \[absent\] to 3 \[severe\]) for each of the 4 specified body regions (head and neck, upper extremities, lower extremities, and trunk). Body area involvement ranged from 0 (0%) to 6 (90-100%). Total EASI score was calculated as a sum of scores of all 4 specified body region. Range for EASI total score is 0 (absent) to 72 (severe). Baseline was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Mean change from Baseline was presented in the form of mean and SD. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Scores on a scale | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1; n= 38,41,39,37,38,32 | -2.58 ± 3.965 | -3.83 ± 4.410 | -3.22 ± 3.585 | -2.51 ± 3.240 | -1.84 ± 2.730 | -1.06 ± 3.660 |
| Week 2; n= 39,39,39,39,33,32 | -4.89 ± 4.052 | -5.69 ± 3.996 | -5.27 ± 3.848 | -4.21 ± 3.337 | -3.18 ± 3.545 | -1.67 ± 3.079 |
| Week 4; n= 38,39,38,39,30,32 | -6.55 ± 3.808 | -7.18 ± 4.534 | -7.42 ± 3.749 | -6.19 ± 3.588 | -4.45 ± 4.180 | -2.94 ± 3.788 |
| Week 8; n= 36,37,34,38,29,27 | -7.00 ± 4.759 | -8.12 ± 4.924 | -8.67 ± 5.039 | -7.62 ± 4.539 | -5.24 ± 5.267 | -4.15 ± 5.190 |
| Week 12; n= 36,37,32,35,28,25 | -7.85 ± 5.000 | -8.16 ± 4.931 | -10.12 ± 4.665 | -8.16 ± 5.077 | -6.05 ± 5.937 | -5.58 ± 5.668 |
| Week 14; n= 34,35,31,33,27,25 | -7.08 ± 3.955 | -7.36 ± 4.683 | -9.07 ± 5.367 | -7.42 ± 4.798 | -6.28 ± 5.335 | -5.44 ± 5.050 |
| Week 16; n= 34,36,31,35,27,25 | -6.45 ± 4.245 | -7.45 ± 5.106 | -8.85 ± 5.654 | -7.67 ± 4.405 | -6.29 ± 6.158 | -5.40 ± 5.315 |
| EW; n= 3,4,7,3,11,11 | -1.03 ± 5.523 | 3.40 ± 4.023 | 3.11 ± 9.042 | -2.97 ± 6.661 | 2.01 ± 4.418 | 3.38 ± 9.746 |
The EASI scoring system is a standard clinical tool for assessing the severity of AD that takes into account the overall severity of erythema, infiltration/papulation, excoriation, and lichenification, as well as the extent of BSA affected with AD. These 4 clinical signs were graded on a 4-point scale (0 \[absent\] to 3 \[severe\]) for each of the 4 specified body regions (head and neck, upper extremities, lower extremities, and trunk). Body area involvement ranged from 0 (0%) to 6 (90-100%). Total EASI score was calculated as a sum of scores of all 4 specified body region. Range for EASI total score is 0 (absent) to 72 (severe). Baseline was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Mean percent change from Baseline was presented in the form of mean and SD. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Percentage Change | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1; n= 38,41,39,37,38,32 | -23.83 ± 42.885 | -34.76 ± 32.718 | -24.19 ± 21.716 | -25.81 ± 28.724 | -16.79 ± 25.777 | -7.51 ± 36.549 |
| Week 2; n= 39,39,39,39,33,32 | -48.70 ± 33.089 | -54.21 ± 29.107 | -42.60 ± 26.428 | -40.41 ± 30.835 | -32.03 ± 32.737 | -13.98 ± 38.616 |
| Week 4; n= 38,39,38,39,30,32 | -64.95 ± 23.948 | -66.40 ± 30.182 | -60.07 ± 23.967 | -55.38 ± 24.465 | -40.74 ± 30.097 | -30.54 ± 36.196 |
| Week 8; n= 36,37,34,38,29,27 | -68.14 ± 28.052 | -73.57 ± 27.204 | -70.52 ± 25.062 | -65.12 ± 26.089 | -50.78 ± 33.026 | -43.15 ± 41.388 |
| Week 12; n= 36,37,32,35,28,25 | -77.19 ± 28.152 | -73.02 ± 25.068 | -80.13 ± 18.602 | -69.49 ± 24.805 | -56.73 ± 38.234 | -60.29 ± 34.253 |
| Week 14; n= 34,35,31,33,27,25 | -71.15 ± 27.875 | -65.53 ± 29.777 | -70.37 ± 31.907 | -64.72 ± 25.594 | -60.26 ± 31.632 | -55.21 ± 31.514 |
| Week 16; n= 34,36,31,35,27,25 | -63.59 ± 36.461 | -63.70 ± 25.833 | -69.89 ± 32.687 | -67.28 ± 25.745 | -57.52 ± 47.140 | -52.47 ± 38.236 |
| EW; n= 3,4,7,3,11,11 | -0.83 ± 98.753 | 42.27 ± 43.950 | 8.74 ± 87.714 | -35.40 ± 66.349 | 13.69 ± 32.424 | 32.55 ± 86.387 |
The IGA is a clinical tool for assessing the current state/severity of a participant's AD. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines. IGA is made without reference to previous scores. The percentage of participants with a minimum 2-grade improvement in IGA score from Baseline at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and early withdrawal (EW) visit was presented in the form of mean and SD. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Percentage of participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1; n= 38,41,39,37,38,32 | 5 | 7 | 0 | 3 | 5 | 6 |
| Week 2; n= 39, 39, 39, 39, 33, 32 | 18 | 21 | 10 | 15 | 15 | 9 |
| Week 4; n= 38,39,38,39,30,32 | 32 | 46 | 26 | 28 | 23 | 13 |
| Week 8; n= 36,37,34,38,29,27 | 44 | 59 | 38 | 45 | 28 | 22 |
| Week 12; n= 36,37,32,35,28,25 | 64 | 51 | 53 | 43 | 39 | 44 |
| Week 14; n= 34,35,31,33,27,25 | 47 | 46 | 55 | 42 | 26 | 36 |
| Week 16; n= 34,36,31,35,27,25 | 35 | 36 | 39 | 43 | 33 | 32 |
| EW; n= 3,4,7,3,11,11 | 33 | 0 | 14 | 33 | 0 | 9 |
The IGA is a clinical tool for assessing the current state/severity of a participant's AD. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines. IGA is made without reference to previous scores. The percentage of participants with an IGA score of 0 or 1 at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW visit was presented in the form of mean and SD. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Percentage of participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1; 38,41,39,37,38,32 | 5 | 5 | 0 | 3 | 3 | 3 |
| Week 2; n= 39,39,39,39,33,32 | 18 | 18 | 10 | 13 | 15 | 9 |
| Week 4; n= 38,39,38,39,30,32 | 32 | 38 | 26 | 23 | 20 | 9 |
| Week 8; n= 36,37,34,38,29,27 | 42 | 54 | 38 | 42 | 28 | 19 |
| Week 12; n= 36,37,32,35,28,25 | 58 | 51 | 50 | 40 | 36 | 44 |
| Week 14; n= 34,35,31,33,27,25 | 44 | 43 | 52 | 36 | 26 | 36 |
| Week 16; n= 34,36,31,35,27,25 | 35 | 36 | 39 | 40 | 30 | 28 |
| EW; n= 3,4,7,3,11,11 | 33 | 0 | 14 | 33 | 0 | 9 |
The EASI scoring system is a standard clinical tool for assessing the severity of AD that takes into account the overall severity of erythema, infiltration/papulation, excoriation, and lichenification, as well as the extent of BSA affected with AD. These 4 clinical signs were graded on a 4-point scale for each of the 4 specified body regions (head and neck, upper extremities, lower extremities, and trunk). Percentage of participants with \>=50 percent improvement in EASI score from Baseline to Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW were presented and statistical analysis was performed using a repeated measures factorial logistic regression model. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Percentage of participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1; n= 38, 41, 39, 37, 38, 32 | 32 | 39 | 13 | 22 | 11 | 13 |
| Week 2; n= 39, 39, 39, 39, 33, 32 | 56 | 56 | 38 | 36 | 33 | 19 |
| Week 4; n= 38, 39, 38, 39, 30, 32 | 76 | 72 | 63 | 59 | 37 | 41 |
| Week 8; n= 36, 37, 34, 38, 29, 27 | 81 | 92 | 85 | 79 | 59 | 56 |
| Week 12; n= 36, 37, 32, 35, 28, 25 | 83 | 84 | 97 | 74 | 64 | 84 |
| Week 14; n= 34, 35, 31, 33, 27, 25 | 85 | 74 | 81 | 76 | 63 | 68 |
| Week 16; n= 34, 36, 31 35, 27, 25 | 76 | 78 | 84 | 71 | 67 | 72 |
| EW; n= 3,4,7,3,11,11 | 33 | 0 | 29 | 33 | 0 | 9 |
The EASI scoring system is a standard clinical tool for assessing the severity of AD that takes into account the overall severity of erythema, infiltration/papulation, excoriation, and lichenification, as well as the extent of BSA affected with AD. These 4 clinical signs were graded on a 4-point scale for each of the 4 specified body regions (head and neck, upper extremities, lower extremities, and trunk). Percentage of participants with \>=75 percent improvement in EASI score from Baseline to Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW were presented and statistical analysis was performed using a repeated measures factorial logistic regression model. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Percentage of participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1; n= 38, 41, 39, 37, 38, 32 | 5 | 12 | 0 | 5 | 0 | 6 |
| Week 2; n= 39, 39, 39, 39, 33, 32 | 21 | 33 | 13 | 21 | 9 | 3 |
| Week 4; n= 38, 39, 38, 39, 30, 32 | 37 | 51 | 29 | 26 | 20 | 9 |
| Week 8; n= 36, 37, 34, 38, 29, 27 | 44 | 57 | 53 | 37 | 31 | 26 |
| Week 12; n= 36, 37, 32, 35, 28, 25 | 67 | 57 | 69 | 46 | 39 | 40 |
| Week 14; n= 34, 35, 31, 33, 27, 25 | 50 | 49 | 68 | 36 | 41 | 36 |
| Week 16; n= 34, 36, 31 35, 27, 25 | 47 | 39 | 61 | 43 | 44 | 32 |
| EW; n= 3,4,7,3,11,11 | 33 | 0 | 14 | 33 | 0 | 9 |
A target lesion of at least 3 centimeter square (cm\^2) was selected at Baseline. The severity of the following signs: erythema, induration/papulation, lichenification, oozing/crusting, and scaling was assessed on a 4-point scale ranging from 0 (absent) to 3 (severe), with higher values indicating greater severity of symptoms. TSS (maximum score 15) was calculated based on these signs. Mean change from Baseline in TSS at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW visit was presented using mean and SD. Baseline value was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Scores on a scale | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1; n= 38, 41, 39, 37, 38, 32 | -1.8 ± 2.04 | -2.7 ± 2.75 | -2.1 ± 1.81 | -1.8 ± 2.02 | -1.9 ± 2.60 | -0.9 ± 2.21 |
| Week 2; n= 39, 39, 39, 39, 33, 32 | -3.6 ± 2.50 | -4.0 ± 2.42 | -3.7 ± 2.45 | -3.3 ± 2.46 | -3.1 ± 2.73 | -1.8 ± 2.73 |
| Week 4; n= 38, 39, 38, 39, 30, 32 | -4.2 ± 2.48 | -4.5 ± 2.39 | -5.1 ± 2.58 | -4.1 ± 2.64 | -3.3 ± 2.68 | -3.0 ± 3.03 |
| Week 8; n= 36, 37, 34, 38, 29, 27 | -4.7 ± 2.37 | -5.4 ± 2.65 | -6.1 ± 2.17 | -5.1 ± 2.34 | -4.7 ± 2.68 | -4.3 ± 3.01 |
| Week 12; n= 36, 37, 32, 35, 28, 25 | -5.8 ± 2.92 | -5.5 ± 2.64 | -7.0 ± 2.38 | -5.5 ± 2.58 | -4.6 ± 2.64 | -5.2 ± 2.97 |
| Week 14; n= 34, 35, 31, 33, 27, 25 | -5.6 ± 2.67 | -5.1 ± 2.19 | -5.5 ± 3.22 | -4.4 ± 3.09 | -5.0 ± 2.72 | -5.0 ± 2.88 |
| Week 16; n= 34, 36, 31, 35, 27, 25 | -5.4 ± 2.98 | -4.9 ± 2.27 | -6.0 ± 2.91 | -5.1 ± 2.65 | -4.8 ± 2.62 | -4.9 ± 2.74 |
| EW; n= 3, 4, 7, 3, 11, 11 | -2.3 ± 4.93 | 0.5 ± 5.26 | -0.4 ± 4.83 | -2.7 ± 3.51 | -1.1 ± 3.65 | -0.1 ± 4.04 |
A target lesion of at least 3 cm\^2 was selected at Baseline. The severity of the following signs: erythema, induration/papulation, lichenification, oozing/crusting, and scaling was assessed on a 4-point scale ranging from 0 (absent) to 3 (severe) , with higher values indicating greater severity of symptoms. TSS (maximum score 15) was calculated based on these signs. Mean percent change from Baseline in TSS at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW visit was presented using mean and SD. Baseline value was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Percentage Change | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1; n= 38, 41, 39, 37, 38, 32 | -23.5 ± 27.99 | -33.7 ± 31.01 | -25.8 ± 21.94 | -22.6 ± 24.78 | -22.0 ± 27.47 | -9.8 ± 28.06 |
| Week 2; n= 39, 39, 39, 39, 33, 32 | -46.7 ± 32.75 | -52.8 ± 28.45 | -44.5 ± 26.15 | -42.4 ± 33.54 | -35.1 ± 29.29 | -17.6 ± 40.06 |
| Week 4; n= 38, 39, 38, 39, 30, 32 | -55.8 ± 31.18 | -60.1 ± 28.58 | -60.3 ± 27.68 | -52.1 ± 33.85 | -37.4 ± 27.29 | -33.5 ± 36.16 |
| Week 8; n= 36, 37, 34, 38, 29, 27 | -61.7 ± 28.14 | -69.1 ± 27.56 | -71.0 ± 20.75 | -65.3 ± 28.31 | -57.4 ± 31.55 | -50.0 ± 35.53 |
| Week 12; n= 36, 37, 32, 35, 28, 25 | -74.3 ± 31.61 | -73.1 ± 31.69 | -80.9 ± 18.59 | -68.6 ± 27.17 | -56.2 ± 30.53 | -62.6 ± 30.39 |
| Week 14; n= 34, 35, 31, 33, 27, 25 | -73.5 ± 30.31 | -71.1 ± 29.53 | -63.0 ± 32.96 | -53.7 ± 35.25 | -59.7 ± 34.87 | -60.2 ± 29.97 |
| Week 16; n= 34, 36, 31, 35, 27, 25 | -69.3 ± 33.20 | -66.0 ± 30.03 | -68.8 ± 30.66 | -63.5 ± 29.78 | -59.8 ± 33.68 | -60.3 ± 31.16 |
| EW; n= 3, 4, 7, 3, 11, 11 | -26.7 ± 64.29 | 1.4 ± 82.20 | -2.9 ± 75.44 | -40.3 ± 56.57 | -7.9 ± 41.91 | 5.0 ± 59.63 |
The severity of the following signs: erythema, induration/papulation, lichenification, oozing/crusting, and scaling was assessed on a 4-point scale ranging from 0 (absent) to 3 (severe) and TSS (maximum score 15) was calculated based on these signs. Mean change from Baseline in individual signs of TSS was presented using mean and SD. Baseline value was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. If the participant had more than 3 missing days during the week, then the weekly average was not calculated and treated as missing data and excluded from the analysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Scores on a scale | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Erythema; Week 1; n= 38, 41, 39, 37, 38, 32 | -0.6 ± 0.55 | -0.8 ± 0.88 | -0.4 ± 0.63 | -0.4 ± 0.55 | -0.4 ± 0.76 | -0.2 ± 0.66 |
| Erythema; Week 2; n= 39, 39, 39, 39, 33, 32 | -1.1 ± 0.70 | -1.1 ± 0.84 | -0.8 ± 0.76 | -0.7 ± 0.75 | -0.6 ± 0.78 | -0.3 ± 0.93 |
| Erythema; Week 4; n= 38, 39, 38, 39, 30, 32 | -1.1 ± 0.69 | -1.3 ± 0.75 | -1.2 ± 0.79 | -0.9 ± 0.79 | -0.8 ± 0.73 | -0.6 ± 0.87 |
| Erythema; Week 8; n= 36, 37, 34, 38, 29, 27 | -1.3 ± 0.70 | -1.5 ± 0.77 | -1.4 ± 0.61 | -1.2 ± 0.73 | -1.2 ± 0.85 | -0.9 ± 1.01 |
| Erythema; Week 12; n= 36, 37, 32, 35, 28, 25 | -1.5 ± 0.84 | -1.5 ± 0.80 | -1.7 ± 0.69 | -1.3 ± 0.84 | -1.1 ± 0.77 | -1.0 ± 0.89 |
| Erythema; Week 14; n= 34, 35, 31, 33, 27, 25 | -1.5 ± 0.83 | -1.4 ± 0.77 | -1.3 ± 0.97 | -1.0 ± 0.75 | -1.2 ± 0.74 | -1.0 ± 0.79 |
| Erythema; Week 16; n= 34, 36 , 31, 35, 27, 25 | -1.5 ± 0.83 | -1.3 ± 0.82 | -1.4 ± 0.92 | -1.1 ± 0.77 | -1.1 ± 0.87 | -1.0 ± 0.68 |
| Erythema; EW; n= 3, 4, 7, 3, 11, 11 | -0.7 ± 1.15 | -0.3 ± 0.96 | -0.4 ± 0.98 | -1.0 ± 1.00 | -0.4 ± 1.12 | -0.1 ± 1.38 |
| Induration/Papulation;Week 1; n=38,41,39,37,38,32 | -0.3 ± 0.48 | -0.6 ± 0.77 | -0.5 ± 0.68 | -0.4 ± 0.60 | -0.3 ± 0.65 | -0.1 ± 0.55 |
| Induration/Papulation;Week 2;n= 39,39,39,39,33,32 | -0.8 ± 0.73 | -1.0 ± 0.87 | -0.8 ± 0.84 | -0.8 ± 0.73 | -0.6 ± 0.87 | -0.4 ± 0.87 |
| Induration/Papulation;Week 4;n= 38,39,38,39,30,32 | -1.0 ± 0.82 | -1.2 ± 0.86 | -1.1 ± 0.78 | -0.9 ± 0.83 | -0.7 ± 0.75 | -0.7 ± 0.79 |
| Induration/Papulation;Week 8;n= 36,37,34,38,29,27 | -1.1 ± 0.65 | -1.2 ± 1.00 | -1.4 ± 0.66 | -1.2 ± 0.69 | -1.0 ± 0.76 | -0.9 ± 0.75 |
| Induration/Papulation;Week 12;n=36,37,32,35,28,25 | -1.4 ± 0.87 | -1.4 ± 0.86 | -1.6 ± 0.72 | -1.2 ± 0.73 | -0.8 ± 0.79 | -1.1 ± 0.86 |
| Induration/Papulation;Week 14;n=34,35,31,33,27,25 | -1.3 ± 0.86 | -1.3 ± 0.64 | -1.3 ± 0.73 | -0.9 ± 0.83 | -0.9 ± 0.75 | -1.1 ± 0.83 |
| Induration/Papulation;Week 16;n=34,36,31,35,27,25 | -1.2 ± 0.82 | -1.2 ± 0.74 | -1.4 ± 0.75 | -1.2 ± 0.82 | -0.8 ± 0.68 | -1.1 ± 0.91 |
| Induration/Papulation; EW; n= 3,4,7,3,11,11 | -0.3 ± 1.53 | 0.0 ± 0.82 | -0.1 ± 1.35 | 0.0 ± 1.00 | -0.3 ± 1.19 | 0.1 ± 1.38 |
| Lichenification; Week 1;n=38,41,39,37,38,32 | -0.3 ± 0.63 | -0.5 ± 0.81 | -0.4 ± 0.60 | -0.4 ± 0.54 | -0.4 ± 0.63 | -0.2 ± 0.42 |
| Lichenification; Week 2;n=39,39,39,39,33,32 | -0.6 ± 0.81 | -0.8 ± 0.78 | -0.7 ± 0.66 | -0.7 ± 0.73 | -0.7 ± 0.78 | -0.4 ± 0.76 |
| Lichenification; Week 4;n=38,39,38,39,30,32 | -0.8 ± 0.81 | -0.9 ± 0.70 | -1.1 ± 0.73 | -0.9 ± 0.84 | -0.6 ± 0.89 | -0.6 ± 0.88 |
| Lichenification; Week 8;n=36,37,34,38,29,27 | -0.9 ± 0.83 | -1.1 ± 0.80 | -1.2 ± 0.67 | -1.1 ± 0.74 | -0.9 ± 0.65 | -1.0 ± 0.76 |
| Lichenification; Week 12;n=36,37,32,35,28,25 | -1.2 ± 0.91 | -1.1 ± 0.75 | -1.5 ± 0.57 | -1.2 ± 0.75 | -1.0 ± 0.67 | -1.3 ± 0.74 |
| Lichenification; Week 14;n=34,35,31,33,27,25 | -1.2 ± 0.84 | -1.0 ± 0.71 | -1.2 ± 0.83 | -1.1 ± 0.70 | -1.0 ± 0.85 | -1.2 ± 0.82 |
| Lichenification; Week 16;n=34,36,31,35,27,25 | -1.1 ± 0.98 | -1.0 ± 0.70 | -1.3 ± 0.73 | -1.1 ± 0.72 | -1.0 ± 0.76 | -1.2 ± 0.65 |
| Lichenification; EW;n= 3,4,7,3,11,11 | -0.7 ± 1.15 | 0.0 ± 0.82 | -0.4 ± 0.98 | -1.0 ± 1.00 | -0.4 ± 0.81 | -0.2 ± 0.98 |
| Oozing/crusting; Week 1;n=38,41,39,37,38,32 | -0.2 ± 0.47 | -0.4 ± 0.62 | -0.4 ± 0.63 | -0.3 ± 0.47 | -0.3 ± 0.91 | -0.2 ± 0.68 |
| Oozing/crusting; Week 2;n=39,39,39,39,33,32 | -0.5 ± 0.60 | -0.4 ± 0.55 | -0.7 ± 0.79 | -0.4 ± 0.55 | -0.5 ± 0.75 | -0.4 ± 0.66 |
| Oozing/crusting; Week 4;n=38,39,38,39,30,32 | -0.6 ± 0.65 | -0.5 ± 0.64 | -0.8 ± 0.86 | -0.6 ± 0.67 | -0.6 ± 0.82 | -0.5 ± 0.80 |
| Oozing/crusting; Week 8;n=36,37,34,38,29,27 | -0.6 ± 0.64 | -0.6 ± 0.75 | -1.0 ± 0.90 | -0.7 ± 0.65 | -0.6 ± 0.78 | -0.7 ± 0.82 |
| Oozing/crusting; Week 12;n=36,37,32,35,28,25 | -0.6 ± 0.60 | -0.6 ± 0.72 | -1.1 ± 0.93 | -0.7 ± 0.66 | -0.7 ± 0.81 | -0.8 ± 0.94 |
| Oozing/crusting; Week 14;n=34,35,31,33,27,25 | -0.6 ± 0.65 | -0.5 ± 0.78 | -0.8 ± 1.00 | -0.5 ± 0.94 | -0.8 ± 0.79 | -0.9 ± 0.83 |
| Oozing/crusting; Week 16;n=34,36,31,35,27,25 | -0.6 ± 0.61 | -0.6 ± 0.77 | -1.0 ± 1.03 | -0.7 ± 0.62 | -0.8 ± 0.75 | -0.8 ± 0.87 |
| Oozing/crusting; EW;n=3,4,7,3,11,11 | -0.3 ± 0.58 | 0.8 ± 1.50 | 0.6 ± 1.40 | 0.0 ± 0.00 | 0.0 ± 0.77 | 0.1 ± 0.70 |
| Scaling; Week 1;n=38,41,39,37,38,32 | -0.3 ± 0.85 | -0.4 ± 0.70 | -0.4 ± 0.68 | -0.3 ± 0.78 | -0.4 ± 0.72 | -0.2 ± 0.63 |
| Scaling; Week 2;n= 39,39,39,39,33,32 | -0.6 ± 0.82 | -0.7 ± 0.68 | -0.6 ± 0.67 | -0.6 ± 0.71 | -0.6 ± 0.78 | -0.3 ± 0.63 |
| Scaling; Week 4;n=38,39,38,39,30,32 | -0.8 ± 0.78 | -0.7 ± 0.69 | -0.8 ± 0.75 | -0.8 ± 0.81 | -0.7 ± 0.71 | -0.6 ± 0.87 |
| Scaling; Week 8;n=36,37,34,38,29,27 | -0.8 ± 0.79 | -0.9 ± 0.66 | -1.1 ± 0.71 | -0.9 ± 0.71 | -1.0 ± 0.76 | -0.8 ± 0.88 |
| Scaling; Week 12;n=36,37,32,35,28,25 | -1.1 ± 0.83 | -0.9 ± 0.70 | -1.2 ± 0.72 | -1.0 ± 0.80 | -1.0 ± 0.67 | -0.9 ± 0.91 |
| Scaling; Week 14;n=34,35,31,33,27,25 | -1.0 ± 0.85 | -0.9 ± 0.73 | -1.0 ± 0.80 | -0.8 ± 0.87 | -1.0 ± 0.81 | -0.9 ± 0.88 |
| Scaling; Week 16;n=34,36,31,35,27,25 | -1.0 ± 0.90 | -0.8 ± 0.75 | -1.0 ± 0.68 | -0.9 ± 0.74 | -1.1 ± 0.70 | -0.8 ± 0.80 |
| Scaling; EW;n=3,4,7,3,11,11 | -0.3 ± 0.58 | 0.0 ± 1.41 | 0.0 ± 0.82 | -0.7 ± 0.58 | -0.1 ± 1.04 | 0.0 ± 0.89 |
The severity of the following signs: erythema, induration/papulation, lichenification, oozing/crusting, and scaling was assessed on a 4-point scale ranging from 0 (absent) to 3 (severe) and TSS (maximum score 15) was calculated based on these signs. Mean percent change from Baseline in individual signs of TSS was presented using mean and SD. Baseline value was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. NA indicates that data were not available. If the participant had more than 3 missing days during the week, then the weekly average was not calculated and treated as missing data and excluded from the analysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Percentage Change | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Erythema; Week 1; n= 38, 41, 39, 36, 38, 30 | -25.9 ± 26.76 | -35.4 ± 37.86 | -17.1 ± 28.74 | -19.9 ± 27.26 | -19.3 ± 34.12 | -8.9 ± 37.07 |
| Erythema; Week 2; n= 39, 39, 39, 38, 33, 30 | -49.6 ± 34.30 | -49.1 ± 35.86 | -35.5 ± 33.15 | -36.0 ± 36.46 | -26.3 ± 39.75 | -12.8 ± 56.34 |
| Erythema; Week 4; n= 38, 39, 38, 38, 30, 30 | -51.3 ± 32.74 | -59.0 ± 32.86 | -55.7 ± 34.28 | -45.6 ± 38.10 | -33.3 ± 37.14 | -30.6 ± 42.23 |
| Erythema; Week 8; n= 36, 37, 34, 37, 29, 25 | -58.8 ± 31.24 | -69.8 ± 33.06 | -65.7 ± 26.89 | -58.6 ± 35.05 | -55.2 ± 40.36 | -44.0 ± 48.80 |
| Erythema; Week 12; n= 36, 37, 32, 34, 28, 23 | -69.9 ± 36.69 | -69.4 ± 37.37 | -77.1 ± 25.66 | -66.7 ± 34.33 | -51.2 ± 36.55 | -52.2 ± 38.70 |
| Erythema; Week 14; n= 34, 35, 31, 32, 27, 23 | -70.6 ± 36.71 | -66.2 ± 37.37 | -55.9 ± 46.66 | -49.5 ± 34.26 | -56.2 ± 35.55 | -48.6 ± 34.05 |
| Erythema; Week 16; n= 34, 36 , 31, 34, 27, 23 | -67.2 ± 36.58 | -59.7 ± 39.11 | -60.2 ± 44.03 | -58.8 ± 36.29 | -50.6 ± 40.95 | -50.0 ± 30.57 |
| Erythema; EW; n= 3, 4, 7, 3, 11, 11 | -33.3 ± 57.74 | -8.3 ± 44.10 | -21.4 ± 48.80 | -50.0 ± 50.00 | -10.6 ± 42.99 | 18.2 ± 87.39 |
| Induration/Papulation;Week 1; n=38,40,37,37,38,32 | -18.0 ± 26.67 | -28.3 ± 33.16 | -21.6 ± 26.02 | -18.0 ± 25.27 | -12.7 ± 41.27 | -3.1 ± 35.78 |
| Induration/Papulation;Week 2;n= 39,38,37,39,33,32 | -43.2 ± 40.05 | -46.9 ± 38.91 | -41.0 ± 40.37 | -40.6 ± 43.05 | -22.7 ± 47.47 | -14.6 ± 55.48 |
| Induration/Papulation;Week 4;n= 38,38,36,39,30,32 | -49.1 ± 45.84 | -61.0 ± 38.22 | -56.5 ± 32.68 | -43.6 ± 51.24 | -31.1 ± 32.38 | -31.8 ± 43.04 |
| Induration/Papulation;Week 8;n= 36,36,33,38,29,27 | -57.9 ± 35.07 | -58.8 ± 43.37 | -70.7 ± 27.96 | -65.8 ± 36.55 | -54.0 ± 46.64 | -44.4 ± 43.85 |
| Induration/Papulation;Week 12;n=36,36,31,35,28,25 | -72.2 ± 46.97 | -68.5 ± 43.60 | -79.6 ± 26.77 | -65.2 ± 34.39 | -41.7 ± 47.90 | -54.7 ± 40.69 |
| Induration/Papulation;Week 14;n=34,34,30,33,27,25 | -65.7 ± 44.18 | -73.5 ± 31.55 | -63.9 ± 32.48 | -46.5 ± 39.69 | -50.0 ± 48.48 | -56.0 ± 39.35 |
| Induration/Papulation;Week 16;n=34,35,30,35,27,25 | -65.7 ± 42.43 | -62.4 ± 38.84 | -67.8 ± 35.81 | -61.0 ± 38.97 | -51.2 ± 43.10 | -52.0 ± 49.14 |
| Induration/Papulation; EW; n= 3,4,6,3,11,11 | 0.0 ± 100.00 | -12.5 ± 62.92 | -16.7 ± 68.31 | 0.0 ± 100.00 | -4.5 ± 56.81 | 27.3 ± 103.35 |
| Lichenification; Week 1;n=34,37,38,37,37,32 | -22.1 ± 39.51 | -30.6 ± 40.73 | -24.6 ± 39.85 | -16.7 ± 33.10 | -19.8 ± 29.88 | -13.5 ± 28.54 |
| Lichenification; Week 2;n=35,36,38,39,32,32 | -38.1 ± 45.83 | -46.3 ± 42.56 | -36.8 ± 37.60 | -38.5 ± 41.56 | -39.1 ± 39.85 | -19.3 ± 46.97 |
| Lichenification; Week 4;n=34,36,37,39,29,32 | -47.1 ± 48.80 | -51.9 ± 36.47 | -56.3 ± 37.34 | -45.3 ± 40.64 | -32.2 ± 46.91 | -23.4 ± 48.61 |
| Lichenification; Week 8;n=33,35,33,38,28,27 | -53.5 ± 47.10 | -62.9 ± 38.58 | -62.1 ± 32.62 | -60.1 ± 39.24 | -53.0 ± 36.59 | -49.4 ± 37.12 |
| Lichenification; Week 12;n=33,35,31,35,27,25 | -71.7 ± 41.56 | -69.0 ± 36.86 | -78.5 ± 23.25 | -64.8 ± 37.44 | -57.4 ± 36.50 | -67.3 ± 35.84 |
| Lichenification; Week 14;n=31,33,30,33,26,25 | -73.7 ± 38.19 | -62.6 ± 43.71 | -59.4 ± 43.92 | -56.6 ± 36.07 | -54.5 ± 40.15 | -60.7 ± 36.92 |
| Lichenification; Week 16;n=31,34,30,35,26,25 | -65.6 ± 45.12 | -60.3 ± 43.81 | -66.1 ± 34.04 | -60.0 ± 37.31 | -57.7 ± 39.79 | -68.7 ± 33.44 |
| Lichenification; EW;n= 2,2,7,3,11,11 | -50.0 ± 70.71 | -25.0 ± 106.07 | -21.4 ± 69.86 | -50.0 ± 50.00 | -16.7 ± 39.44 | -9.1 ± 62.52 |
| Oozing/crusting; Week 1;n=24,21,26,27,27,22 | -29.2 ± 52.99 | -61.9 ± 47.18 | -40.4 ± 46.95 | -40.7 ± 48.11 | -44.4 ± 65.54 | -20.5 ± 50.38 |
| Oozing/crusting; Week 2;n=24,21,27,28,22,23 | -64.6 ± 47.73 | -64.3 ± 42.26 | -75.9 ± 37.65 | -51.8 ± 48.08 | -62.9 ± 44.52 | -37.0 ± 43.22 |
| Oozing/crusting; Week 4;n= 24,21,27,28,21,24 | -75.0 ± 44.23 | -69.0 ± 43.23 | -79.0 ± 44.96 | -76.8 ± 41.90 | -68.3 ± 43.75 | -45.8 ± 55.00 |
| Oozing/crusting; Week 8;n=23,20,25,27,21,21 | -82.6 ± 38.76 | -97.5 ± 11.18 | -84.7 ± 33.99 | -85.2 ± 36.20 | -65.9 ± 43.29 | -59.5 ± 56.17 |
| Oozing/crusting; Week 12;n=23,20,23,25,21,19 | -84.8 ± 35.15 | -87.5 ± 31.93 | -97.8 ± 10.43 | -86.0 ± 33.91 | -74.6 ± 40.35 | -73.7 ± 71.43 |
| Oozing/crusting; Week 14;n=22,19,23,23,21,19 | -86.4 ± 35.13 | -73.7 ± 56.20 | -84.8 ± 32.14 | -80.4 ± 39.14 | -84.9 ± 33.29 | -76.3 ± 42.06 |
| Oozing/crusting; Week 16;n=22,20,23,25,21,19 | -79.5 ± 39.82 | -80.0 ± 41.04 | -84.8 ± 35.15 | -84.0 ± 34.52 | -75.4 ± 41.37 | -71.1 ± 56.06 |
| Oozing/crusting; EW;n=1,1,4,2,5,5 | -100.0 ± NA | 0.0 ± NA | -12.5 ± 103.08 | 0.0 ± 0.00 | -20.0 ± 44.72 | -20.0 ± 44.72 |
| Scaling; Week 1;n=34,36,34,35,36,29 | -28.4 ± 52.79 | -36.1 ± 47.22 | -32.8 ± 47.76 | -19.5 ± 58.23 | -24.1 ± 41.87 | -8.6 ± 42.40 |
| Scaling; Week 2;n= 35,34,34,37,31,30 | -47.1 ± 45.28 | -64.7 ± 45.28 | -53.4 ± 42.60 | -44.1 ± 51.10 | -36.6 ± 40.69 | -12.8 ± 43.04 |
| Scaling; Week 4;n=35,34,34,37,28,30 | -57.1 ± 45.61 | -69.1 ± 40.85 | -68.1 ± 47.38 | -51.8 ± 52.08 | -38.1 ± 36.81 | -33.3 ± 53.07 |
| Scaling; Week 8;n=33,32,30,36,27,25 | -57.6 ± 50.19 | -81.3 ± 35.36 | -81.7 ± 30.75 | -67.1 ± 43.00 | -59.3 ± 38.49 | -50.0 ± 52.04 |
| Scaling; Week 12;n=33,32,29,33,26,23 | -75.8 ± 41.69 | -84.4 ± 32.22 | -82.8 ± 30.69 | -71.2 ± 48.46 | -64.7 ± 37.51 | -54.3 ± 52.03 |
| Scaling; Week 14;n=31,30,28,31,25,23 | -74.2 ± 40.56 | -73.3 ± 48.66 | -70.2 ± 39.11 | -60.2 ± 63.78 | -62.0 ± 39.24 | -52.2 ± 43.90 |
| Scaling; Week 16;n=31,31,28,33,25,23 | -75.8 ± 48.08 | -66.1 ± 50.64 | -72.0 ± 36.87 | -65.7 ± 44.08 | -70.7 ± 35.45 | -51.4 ± 51.23 |
| Scaling; EW;n=2,4,5,3,9,9 | -50.0 ± 70.71 | 0.0 ± 141.42 | -10.0 ± 74.16 | -50.0 ± 50.00 | -5.6 ± 76.83 | 0.0 ± 70.71 |
The extent of BSA affected by AD is a general indicator of disease severity and the assessment of BSA with AD was performed separately for four body surface regions: the head (h), the upper extremities (u), the trunk (t) and the lower extremities (l), corresponding to 10, 20, 30, and 40 percent of the total body area, respectively. Mean change from Baseline in percent BSA was presented using mean and SD at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW visit. Baseline was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Percentage of surface area | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1; n= 38, 41, 39, 37, 38, 32 | -2.37 ± 4.774 | -3.57 ± 5.498 | -2.44 ± 4.313 | -1.52 ± 6.078 | -0.33 ± 6.591 | -0.25 ± 4.411 |
| Week 2; n= 39, 39, 39, 39, 33, 32 | -4.99 ± 7.330 | -7.07 ± 6.639 | -4.88 ± 5.243 | -3.78 ± 5.897 | -2.01 ± 6.484 | -0.04 ± 4.698 |
| Week 4; n= 38, 39, 38, 39, 30, 32 | -7.37 ± 6.276 | -9.76 ± 8.581 | -7.47 ± 7.567 | -7.07 ± 6.382 | -2.93 ± 7.772 | -2.05 ± 6.517 |
| Week 8; n= 36, 37, 34, 38, 29, 27 | -9.23 ± 8.425 | -11.70 ± 9.208 | -10.89 ± 9.692 | -8.56 ± 6.217 | -5.41 ± 7.961 | -3.33 ± 7.264 |
| Week 12; n= 36, 37, 32, 35, 28, 25 | -11.19 ± 8.643 | -11.55 ± 9.690 | -12.18 ± 9.581 | -9.81 ± 7.717 | -6.00 ± 8.424 | -5.44 ± 8.079 |
| Week 14; n= 34, 35, 31, 33, 27, 25 | -9.25 ± 7.121 | -9.85 ± 9.446 | -11.26 ± 10.262 | -9.26 ± 7.529 | -5.60 ± 7.575 | -5.80 ± 6.987 |
| Week 16; n= 34, 36, 31, 35, 27, 25 | -8.19 ± 7.826 | -9.93 ± 8.820 | -10.92 ± 9.903 | -9.25 ± 8.399 | -5.66 ± 7.695 | -5.53 ± 7.227 |
| EW; n= 3, 4, 7, 3, 11, 11 | -2.60 ± 4.613 | 4.63 ± 9.586 | 5.36 ± 21.468 | 3.20 ± 14.468 | 3.36 ± 9.492 | 7.50 ± 18.476 |
The IGA is a clinical tool for assessing the current state/severity of a participant's AD. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines. IGA is made without reference to previous scores. Score ranges from 0 (clear) to 4 (severe). Higher values represent a severe disease. Mean change from Baseline in IGA score was presented using mean and SD at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW visit. Baseline was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Scores on a scale | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1; n= 38, 41, 39, 37, 38, 32 | -0.5 ± 0.60 | -0.6 ± 0.67 | -0.3 ± 0.48 | -0.4 ± 0.55 | -0.3 ± 0.58 | -0.4 ± 0.62 |
| Week 2; n= 39, 39, 39, 39, 33, 32 | -1.0 ± 0.69 | -0.9 ± 0.70 | -0.6 ± 0.67 | -0.7 ± 0.79 | -0.7 ± 0.72 | -0.5 ± 0.72 |
| Week 4; n= 38, 39, 38, 39, 30, 32 | -1.3 ± 0.86 | -1.4 ± 0.81 | -1.1 ± 0.77 | -1.0 ± 0.81 | -1.0 ± 0.72 | -0.7 ± 0.82 |
| Week 8; n= 36, 37, 34, 38, 29, 27 | -1.4 ± 0.83 | -1.6 ± 0.82 | -1.3 ± 0.84 | -1.4 ± 0.85 | -1.2 ± 0.60 | -1.0 ± 0.88 |
| Week 12; n= 36, 37, 32, 35, 28, 25 | -1.7 ± 0.96 | -1.6 ± 0.83 | -1.6 ± 0.76 | -1.5 ± 0.95 | -1.3 ± 0.72 | -1.2 ± 0.78 |
| Week 14; n= 34, 35, 31, 33, 27, 25 | -1.5 ± 1.08 | -1.4 ± 0.77 | -1.5 ± 0.99 | -1.3 ± 0.92 | -1.2 ± 0.85 | -1.2 ± 0.75 |
| Week 16; n= 34, 36, 31, 35, 27, 25 | -1.2 ± 1.07 | -1.2 ± 0.74 | -1.4 ± 0.91 | -1.3 ± 0.94 | -1.3 ± 0.90 | -1.1 ± 0.73 |
| EW; n= 3, 4, 7, 3, 11, 11 | -1.3 ± 1.53 | 0.3 ± 0.50 | -0.6 ± 0.98 | -1.0 ± 1.00 | 0.1 ± 0.30 | 0.0 ± 0.89 |
The IGA is a clinical tool for assessing the current state/severity of a participant's AD. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines. IGA is made without reference to previous scores. The percentage of participants who have an IGA score of clear or almost clear and a minimum 2 grade improvement from Baseline to each study visit in IGA score was presented. The statistical analysis was performed using a repeated measures factorial logistic regression model with covariates for dose, frequency of administration, and study day as well as a dose by frequency interaction term. The analysis was performed on ITT Population which comprised of all randomized participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category title).
| Percentage of participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1; n= 38,41,39,37,38,32 | 5 | 5 | 0 | 3 | 3 | 3 |
| Week 2; n= 39,39,39,39,33,32 | 18 | 18 | 10 | 13 | 15 | 9 |
| Week 4; n= 38,39,38,39,30,32 | 32 | 38 | 26 | 23 | 20 | 9 |
| Week 8; n= 36,37,34,38,29,27 | 42 | 54 | 38 | 42 | 28 | 19 |
| Week 12; n= 36,37,32,35,28,25 | 58 | 51 | 50 | 40 | 36 | 44 |
| Week 14; n= 34,35,31,33,27,25 | 44 | 43 | 52 | 36 | 26 | 36 |
| Week 16; n= 34,36,31,35,27,25 | 35 | 36 | 39 | 40 | 30 | 28 |
| EW; n= 3,4,7,3,11,11 | 33 | 0 | 14 | 33 | 0 | 9 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth effect, other situations and is associated with liver injury or impaired liver function. Treatment emergent AEs (TEAE) is defined as AE occurred on or after study treatment start date and on or before last visit. Number of participants with AEs and serious TEAEs were presented. The analysis was performed on Safety population which comprised of all participants who receive at least one dose of study treatment.
| Participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| TEAEs | 28 | 22 | 20 | 23 | 19 | 15 |
| Serious TEAEs | 1 | 0 | 0 | 0 | 0 | 0 |
Participants were asked to use a 5-point tolerability scale from 0 (none) to 4 (severe) to assess the presence and degree of burning/stinging and itching at the application sites that has generally been experienced following application of the study treatment. The score represented an 'average' across all application sites. A score of 3 or 4 was reported as an AE. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1; none; n= 38,40,39,37,38,33 | 19 | 25 | 25 | 21 | 15 | 22 |
| Week 1; slight; n= 38,40,39,37,38,33 | 6 | 10 | 5 | 6 | 9 | 5 |
| Week 1; mild; n= 38,40,39,37,38,33 | 9 | 3 | 2 | 8 | 6 | 3 |
| Week 1; Moderate; n= 38,40,39,37,38,33 | 2 | 2 | 6 | 2 | 7 | 2 |
| Week 1; severe; n= 38,40,39,37,38,33 | 2 | 0 | 1 | 0 | 1 | 1 |
| Week 2; none; n= 39,37,39,39,33,32 | 26 | 27 | 33 | 20 | 16 | 18 |
| Week 2; slight;n= 39,37,39,39,33,32 | 5 | 5 | 1 | 11 | 6 | 5 |
| Week 2; mild; n= 39,37,39,39,33,32 | 3 | 4 | 4 | 4 | 8 | 5 |
| Week 2; moderate; n= 39,37,39,39,33,32 | 4 | 0 | 1 | 3 | 2 | 2 |
| Week 2; severe; n= 39,37,39,39,33,32 | 1 | 1 | 0 | 1 | 1 | 2 |
| Week 4; none; n= 38, 39, 38,39,29,32 | 26 | 26 | 27 | 27 | 15 | 21 |
| Week 4; slight; n= 38, 39, 38,39,29,32 | 7 | 8 | 5 | 9 | 8 | 2 |
| Week 4; mild; n= 38, 39, 38,39,29,32 | 3 | 4 | 6 | 2 | 4 | 5 |
| Week 4; moderate; n= 38, 39, 38,39,29,32 | 2 | 1 | 0 | 1 | 2 | 3 |
| Week 4; severe; n= 38, 39, 38,39,29,32 | 0 | 0 | 0 | 0 | 0 | 1 |
| Week 8; none; n= 36, 37, 34, 38, 29, 28 | 25 | 28 | 23 | 29 | 19 | 17 |
| Week 8; slight; n= 36, 37, 34, 38, 29, 28 | 6 | 6 | 8 | 7 | 5 | 5 |
| Week 8; mild; n= 36, 37, 34, 38, 29, 28 | 3 | 2 | 2 | 2 | 3 | 3 |
| Week 8; moderate; n= 36, 37, 34, 38, 29, 28 | 1 | 1 | 1 | 0 | 1 | 3 |
| Week 8; severe; n= 36, 37, 34, 38, 29, 28 | 1 | 0 | 0 | 0 | 1 | 0 |
| Week 12; none; n= 36, 37, 32, 35, 28, 28 | 24 | 27 | 26 | 27 | 16 | 23 |
| Week 12; slight; n= 36, 37, 32, 35, 28, 28 | 6 | 8 | 3 | 6 | 8 | 3 |
| Week 12; mild; n= 36, 37, 32, 35, 28, 28 | 5 | 1 | 3 | 2 | 3 | 0 |
| Week 12; moderate; n= 36, 37, 32, 35, 28, 28 | 1 | 0 | 0 | 0 | 1 | 0 |
| Week 12; severe; n= 36, 37, 32, 35, 28, 28 | 0 | 1 | 0 | 0 | 0 | 2 |
| Week 14; none; n= 34,35,32,33,31,29 | 26 | 29 | 27 | 26 | 22 | 22 |
| Week 14; slight; n= 34,35,32,33,31,29 | 4 | 5 | 4 | 5 | 4 | 4 |
| Week 14; mild; n= 34,35,32,33,31,29 | 3 | 0 | 0 | 2 | 2 | 2 |
| Week 14; moderate; n= 34,35,32,33,31,29 | 1 | 1 | 1 | 0 | 2 | 1 |
| Week 14; severe; n= 34,35,32,33,31,29 | 0 | 0 | 0 | 0 | 1 | 0 |
| EW; none; n= 3,4,7,3,11,11 | 2 | 1 | 4 | 2 | 3 | 7 |
| EW; slight; n= 3,4,7,3,11,11 | 0 | 1 | 0 | 0 | 4 | 0 |
| EW; mild; n= 3,4,7,3,11,11 | 1 | 1 | 0 | 0 | 0 | 1 |
| EW; moderate; n= 3,4,7,3,11,11 | 0 | 1 | 2 | 1 | 1 | 2 |
| EW; severe; n= 3,4,7,3,11,11 | 0 | 0 | 1 | 0 | 3 | 1 |
Blood samples were collected to evaluate change from Baseline in albumin and total protein values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
| Gram per Liter (G/L) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Albumin; Week 2; n=38,39,38,39,33,32 | -1.2 ± 2.96 | -1.3 ± 1.89 | -2.2 ± 2.96 | -1.4 ± 2.02 | -1.2 ± 3.91 | -1.2 ± 2.17 |
| Albumin; Week 4; n=38,39,38,38,30,32 | -1.1 ± 2.87 | -0.6 ± 2.17 | -1.9 ± 2.49 | -1.3 ± 2.74 | -1.2 ± 2.46 | -0.7 ± 2.74 |
| Albumin; Week 8; n= 35,37,34,38,29,28 | -1.7 ± 2.47 | -1.0 ± 1.86 | -1.9 ± 2.38 | -1.1 ± 2.29 | -1.4 ± 2.54 | -1.4 ± 3.14 |
| Albumin; Week 12; n= 36,37,32,35,28,28 | -1.1 ± 2.48 | -1.2 ± 2.65 | -2.2 ± 2.35 | -1.7 ± 2.47 | -1.6 ± 2.79 | -0.9 ± 2.09 |
| Albumin; Week 14; n= 33,35,32,34,31,29 | -1.6 ± 2.36 | -1.5 ± 2.41 | -2.0 ± 2.48 | -1.6 ± 3.04 | -2.0 ± 2.70 | -0.9 ± 2.21 |
| Albumin; EW;n = 3,3,7,3,11,11 | -1.3 ± 4.04 | -3.3 ± 2.52 | -3.0 ± 1.29 | -0.7 ± 0.58 | -0.7 ± 2.87 | -2.5 ± 2.84 |
| Total protein; Week 2; n= 38,39,38,39,33,32 | -1.5 ± 4.49 | -2.2 ± 2.84 | -2.3 ± 4.48 | -2.0 ± 3.34 | -1.9 ± 6.66 | -1.6 ± 3.31 |
| Total protein; Week 4; n= 38,39,38,38,30,32 | -1.9 ± 4.32 | -1.1 ± 3.49 | -2.4 ± 4.43 | -1.7 ± 5.12 | -2.3 ± 3.86 | -1.1 ± 4.62 |
| Total protein; Week 8; n= 35,37,34,38,29,28 | -2.8 ± 3.91 | -2.1 ± 3.02 | -2.8 ± 4.46 | -1.7 ± 3.89 | -1.7 ± 4.09 | -1.8 ± 4.82 |
| Total protein; Week 12; n= 36,37,32,35,28,28 | -2.0 ± 4.16 | -2.5 ± 4.43 | -3.8 ± 4.40 | -2.4 ± 4.07 | -2.2 ± 5.38 | -1.0 ± 3.18 |
| Total protein; Week 14; n= 33,35,32,34,31,29 | -3.0 ± 3.80 | -2.4 ± 3.23 | -3.3 ± 4.07 | -2.0 ± 4.75 | -2.3 ± 4.26 | -1.3 ± 3.84 |
| Total protein; EW; n= 3,3,7,3,11,11 | -2.3 ± 6.43 | -4.0 ± 2.00 | -2.0 ± 2.16 | -1.0 ± 2.00 | -1.4 ± 3.64 | -3.0 ± 5.08 |
Blood samples were collected to evaluate change from Baseline in Alk.phosph., ALT, AST and GGT values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
| International unit per liter (IU/L) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Alk.Phosph.; Week 2; n= 38,39,38,39,33,32 | 3.7 ± 14.58 | -1.7 ± 12.24 | 3.7 ± 21.04 | -2.3 ± 13.49 | -2.3 ± 15.32 | -2.0 ± 8.70 |
| Alk.Phosph.; Week 4; n= 38,39,38,38,30,32 | 2.1 ± 15.59 | -0.4 ± 12.17 | 1.7 ± 15.22 | -2.7 ± 12.36 | -3.8 ± 16.24 | -3.9 ± 9.79 |
| Alk.Phosph.; Week 8; n= 35,37,34,38,29,28 | 2.0 ± 12.40 | -0.7 ± 9.39 | -1.2 ± 12.85 | -4.8 ± 18.15 | -1.6 ± 19.08 | -5.7 ± 12.03 |
| Alk.Phosph.; Week 12; n= 36,37,32,35,28,28 | 3.1 ± 15.36 | -0.4 ± 10.14 | -5.1 ± 18.47 | -6.3 ± 17.29 | -8.1 ± 21.60 | -7.8 ± 15.34 |
| Alk. Phosph.; Week 14; n= 33,35,32,34,31,29 | -1.4 ± 13.46 | -3.0 ± 17.56 | -7.2 ± 19.31 | -7.2 ± 20.07 | -6.5 ± 24.86 | -8.3 ± 14.83 |
| Alk.Phosph.; EW; n= 3,3,7,3,11,11 | -2.3 ± 27.74 | 5.3 ± 12.50 | 8.0 ± 18.13 | 0.3 ± 9.87 | 0.9 ± 6.74 | -0.5 ± 7.39 |
| ALT; Week 2; n= 38,39,38,39,33,32 | 3.6 ± 21.02 | -1.8 ± 3.92 | 7.7 ± 28.01 | 1.5 ± 12.52 | 0.2 ± 7.21 | 0.2 ± 6.06 |
| ALT; Week 4; n= 38,39,38,38,30,32 | -0.8 ± 9.20 | -1.1 ± 5.23 | 2.7 ± 8.07 | 1.7 ± 9.28 | 0.3 ± 7.63 | 0.6 ± 4.55 |
| ALT; Week 8; n= 35,37,34,38,29,28 | 4.9 ± 30.93 | -1.4 ± 7.00 | 1.2 ± 6.77 | -1.5 ± 3.98 | -2.0 ± 6.06 | 0.3 ± 5.16 |
| ALT; Week 12; n= 36,37,32,35,28,28 | -0.3 ± 12.51 | -3.1 ± 4.78 | -1.4 ± 4.13 | -0.6 ± 4.64 | 0.8 ± 7.97 | -0.2 ± 5.58 |
| ALT; Week 14; n= 33,35,32,34,31,29 | 3.3 ± 24.10 | -3.2 ± 5.47 | -0.9 ± 4.51 | -1.0 ± 3.93 | -0.5 ± 5.58 | -0.8 ± 3.15 |
| ALT; EW; n= 3,3,7,3,11,11 | 13.0 ± 37.64 | -3.7 ± 16.62 | 11.3 ± 36.60 | 2.0 ± 6.56 | -1.7 ± 4.73 | 3.3 ± 7.70 |
| AST; Week 2; n= 38,39,38,39,33,32 | 1.6 ± 9.36 | -1.3 ± 2.98 | 3.1 ± 13.84 | 0.2 ± 4.99 | -0.8 ± 4.99 | 0.5 ± 3.54 |
| AST; Week 4; n=38,39,38,38,30,32 | -0.4 ± 5.24 | -1.1 ± 4.18 | 1.0 ± 6.37 | 1.1 ± 6.81 | 0.0 ± 5.68 | 0.5 ± 4.17 |
| AST; Week 8; n= 35,37,34,38,29,28 | 18.4 ± 97.92 | -0.9 ± 5.06 | 0.2 ± 4.80 | -1.1 ± 4.56 | -1.9 ± 6.05 | -0.1 ± 5.80 |
| AST; Week 12; n=36,37,32,35,28,28 | 0.1 ± 8.54 | -1.2 ± 4.67 | -1.3 ± 5.12 | -0.7 ± 4.90 | 0.9 ± 6.88 | 0.2 ± 5.20 |
| AST; Week 14; n= 33,35,32,34,31,29 | 4.4 ± 28.19 | -2.2 ± 4.89 | -1.3 ± 3.92 | -1.1 ± 3.48 | 0.5 ± 8.12 | 0.0 ± 4.49 |
| AST; EW; n= 3,3,7,3,11,11 | 4.7 ± 8.62 | 1.7 ± 14.57 | 4.0 ± 12.83 | 3.0 ± 1.73 | -0.8 ± 2.14 | 3.1 ± 6.30 |
| GGT; Week 2; n= 38,39,38,39,33,32 | -0.3 ± 6.36 | -1.3 ± 4.61 | 4.0 ± 13.82 | 0.7 ± 3.49 | -0.9 ± 8.04 | -2.9 ± 9.86 |
| GGT; Week 4; n= 38,39,38,38,30,32 | -2.1 ± 9.47 | -0.8 ± 4.01 | 1.3 ± 6.38 | 0.9 ± 4.87 | 0.1 ± 10.95 | -1.0 ± 4.79 |
| GGT; Week 8; n= 35,37,34,38,29,28 | -2.0 ± 14.19 | -1.2 ± 4.80 | 1.6 ± 10.32 | -0.5 ± 6.96 | -0.2 ± 11.68 | 0.4 ± 5.73 |
| GGT; Week 12; n= 36,37,32,35,28,28 | -1.8 ± 14.77 | -1.6 ± 4.05 | 0.8 ± 8.38 | 1.1 ± 4.52 | 1.7 ± 11.65 | 1.9 ± 7.12 |
| GGT; Week 14; n= 33,35,32,34,31,29 | -2.2 ± 15.76 | -1.0 ± 3.43 | 0.7 ± 4.93 | 1.0 ± 3.63 | 0.1 ± 8.19 | -0.3 ± 3.07 |
| GGT; EW; n= 3,3,7,3,11,11 | 5.7 ± 31.01 | -8.0 ± 16.52 | 3.7 ± 9.48 | -0.7 ± 7.23 | -1.9 ± 8.19 | -4.8 ± 17.11 |
Blood samples were collected to evaluate change from Baseline in direct and total bilirubin, creatinine and urate values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
| Micromoles per liter (µmol/L) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Direct bilirubin; Week 2; n= 38,39,38,39,33,32 | -0.1 ± 0.98 | -0.3 ± 1.08 | -0.5 ± 1.18 | -0.1 ± 1.07 | 0.0 ± 1.66 | -0.3 ± 1.15 |
| Direct bilirubin; Week 4; n= 38,39,38,38,30,32 | -0.1 ± 1.18 | -0.3 ± 0.82 | -0.5 ± 1.18 | -0.2 ± 1.02 | 0.1 ± 1.23 | -0.4 ± 0.94 |
| Direct bilirubin; Week 8; n= 35,37,34, 38,29,28 | 0.1 ± 1.41 | -0.2 ± 0.99 | -0.4 ± 1.08 | -0.2 ± 1.26 | 0.1 ± 1.36 | -0.5 ± 1.17 |
| Direct bilirubin; Week 12; n= 36,37,32,35,28,28 | 0.3 ± 1.19 | 0.0 ± 1.15 | -0.4 ± 0.94 | -0.2 ± 1.17 | 0.0 ± 1.33 | -0.1 ± 1.21 |
| Direct bilirubin; Week 14; n= 33,35,32,34,31,29 | -0.1 ± 1.17 | -0.2 ± 1.32 | 0.1 ± 1.19 | -0.2 ± 1.07 | 0.0 ± 1.26 | -0.3 ± 1.58 |
| Direct bilirubin; EW; n= 3,3,7,3,11,11 | 0.0 ± 2.00 | -0.7 ± 1.15 | -0.6 ± 0.98 | -0.7 ± 1.15 | -0.5 ± 1.81 | 0.0 ± 1.26 |
| Total bilirubin; Week 2; n=38,39,38,39,33,32 | -1.1 ± 3.21 | -0.8 ± 3.23 | -2.2 ± 3.37 | -0.6 ± 2.64 | -0.4 ± 5.49 | -0.1 ± 2.80 |
| Total bilirubin; Week 4; n= 38,39,38,38,30,32 | -1.2 ± 3.18 | -0.8 ± 2.54 | -1.5 ± 3.11 | -1.4 ± 3.15 | 0.3 ± 4.27 | 0.0 ± 2.16 |
| Total bilirubin; Week 8; n= 35,37,34, 38,29,28 | 0.0 ± 4.97 | -0.3 ± 2.93 | -1.8 ± 3.24 | -0.8 ± 4.50 | -0.1 ± 5.06 | -1.1 ± 2.14 |
| Total bilirubin; Weel 12; n= 36,37,32,35,28,28 | 0.5 ± 4.15 | 0.1 ± 2.26 | -1.9 ± 2.56 | -0.9 ± 3.30 | 0.6 ± 4.42 | -0.1 ± 3.17 |
| Total bilirubin; Week 14; n= 33,35,32,34,31,29 | -0.1 ± 2.81 | -0.4 ± 3.90 | 0.0 ± 4.10 | -0.6 ± 3.43 | 0.1 ± 3.92 | -0.4 ± 4.19 |
| Total bilirubin; EW; n = 3,3,7,3,11,11 | -1.3 ± 5.77 | -2.0 ± 2.00 | -0.9 ± 3.44 | -0.7 ± 1.15 | 0.5 ± 4.82 | -0.4 ± 4.27 |
| Creatinine; Week 2; n= 38,39,38,39,33,32 | -3.00 ± 10.771 | -3.65 ± 6.186 | -3.46 ± 7.165 | -0.84 ± 7.294 | -1.56 ± 10.461 | 0.11 ± 8.059 |
| Creatinine; Week 4; n= 38,39,38,38,30,32 | -0.04 ± 11.471 | -3.30 ± 6.974 | -1.14 ± 7.897 | 0.51 ± 8.990 | -1.19 ± 10.945 | 3.70 ± 14.019 |
| Creatinine; Week 8; n= 35,37,34, 38,29,28 | -2.03 ± 12.571 | -1.70 ± 8.249 | -0.29 ± 8.357 | -0.04 ± 8.114 | -0.58 ± 11.799 | -0.51 ± 7.530 |
| Creatinine; Week 12; n= 36,37,32,35,28,28 | -1.84 ± 11.918 | -1.41 ± 9.573 | 0.16 ± 5.886 | 1.03 ± 7.618 | -0.70 ± 10.789 | 1.58 ± 6.241 |
| Creatinine; Week 14; n= 33,35,32,34,31,29 | 2.04 ± 10.306 | -1.48 ± 9.986 | 2.77 ± 7.351 | 3.17 ± 7.990 | -0.05 ± 7.859 | 1.52 ± 5.860 |
| Creatinine; EW; n=3,3,7,3,11,11 | 1.20 ± 2.651 | -5.33 ± 2.650 | -8.19 ± 9.071 | -4.13 ± 8.251 | -1.35 ± 8.386 | 0.09 ± 11.172 |
| Urate; Week 2; n= 38,39,38,39,33,32 | -26.1 ± 74.09 | -7.9 ± 41.56 | -14.5 ± 43.91 | 7.9 ± 49.96 | 0.0 ± 50.19 | 2.5 ± 38.44 |
| Urate; Week 4; n=38,39,38,38,30,32 | -18.7 ± 58.92 | -8.7 ± 39.21 | -2.9 ± 52.96 | 3.9 ± 59.84 | -2.7 ± 62.69 | 24.1 ± 62.21 |
| Urate; Week 8; n=35,37,34, 38,29,28 | -20.0 ± 60.44 | -0.5 ± 52.54 | -7.9 ± 51.63 | -5.5 ± 59.76 | 12.8 ± 44.07 | 12.9 ± 59.25 |
| Urate; Week 12; n=36,37,32,35,28,28 | -20.8 ± 70.48 | -5.1 ± 93.20 | -14.7 ± 46.97 | 2.6 ± 60.89 | 6.8 ± 51.43 | 5.0 ± 46.79 |
| Urate; Week 14; n=33,35,32,34,31,29 | -10.9 ± 58.44 | -5.4 ± 46.86 | 3.8 ± 48.64 | 15.9 ± 61.50 | 5.2 ± 56.32 | 17.2 ± 43.33 |
| Urate; EW; n=3,3,7,3,11,11 | -6.7 ± 20.82 | -16.7 ± 15.28 | -22.9 ± 39.46 | -16.7 ± 85.05 | 0.9 ± 42.30 | 8.2 ± 43.55 |
Blood samples were collected to evaluate change from Baseline in calcium, chloride, CO2, glucose, potassium, sodium and BUN values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
| Millimoles per liter (mmol/L) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Calcium; Week 2; n= 38,39,38,39,33,32 | -0.042 ± 0.0941 | -0.037 ± 0.0918 | -0.067 ± 0.0970 | -0.022 ± 0.0822 | -0.024 ± 0.1346 | -0.027 ± 0.0758 |
| Calcium; Week 4; n= 38,39,38,38,30,32 | -0.037 ± 0.1076 | -0.014 ± 0.0899 | -0.050 ± 0.0873 | -0.028 ± 0.0840 | -0.031 ± 0.0952 | -0.031 ± 0.0900 |
| Calcium; Week 8; n=35,37,34,38,29,28 | -0.053 ± 0.0939 | -0.024 ± 0.0973 | -0.063 ± 0.0800 | -0.025 ± 0.0754 | -0.035 ± 0.0989 | -0.038 ± 0.0788 |
| Calcium; Week 12; n=36,37,32,35,28,28 | -0.022 ± 0.0928 | -0.028 ± 0.0861 | -0.061 ± 0.0934 | -0.029 ± 0.0911 | -0.026 ± 0.1112 | -0.004 ± 0.0596 |
| Calcium; Week 14; n=33,35,32,34,31,29 | -0.022 ± 0.0793 | -0.019 ± 0.0787 | -0.037 ± 0.0964 | -0.019 ± 0.0868 | -0.028 ± 0.0897 | -0.024 ± 0.0668 |
| Calcium; EW; n= 3,3,7,3,11,11 | -0.073 ± 0.1102 | -0.053 ± 0.1405 | -0.003 ± 0.1122 | -0.047 ± 0.0503 | -0.025 ± 0.1092 | -0.038 ± 0.0914 |
| Chloride; Week 2; n= 38,39,38,39,33,32 | 0.5 ± 2.68 | 0.9 ± 2.32 | 0.2 ± 2.68 | 0.6 ± 2.22 | -0.5 ± 2.49 | 0.4 ± 2.27 |
| Chloride; Week 4; n=38,39,38,38,30,32 | 0.5 ± 2.54 | 0.1 ± 2.31 | 0.5 ± 2.05 | 0.3 ± 2.26 | -0.4 ± 2.01 | 0.5 ± 2.38 |
| Chloride; Week 8; n= 35,37,34,38,29,28 | 1.0 ± 2.32 | 0.5 ± 1.99 | 0.5 ± 2.27 | -0.3 ± 2.45 | -0.4 ± 2.21 | 0.5 ± 2.86 |
| Chloride; Week 12; n= 36,37,32,35,28,28 | 0.1 ± 2.57 | 0.7 ± 2.31 | 0.3 ± 1.85 | 0.5 ± 2.44 | -0.4 ± 1.83 | -0.1 ± 2.76 |
| Chloride; Week 14; n=33,35,32,34,31,29 | 0.9 ± 2.34 | 0.4 ± 1.82 | 0.1 ± 2.87 | -0.1 ± 2.40 | -0.3 ± 2.32 | 0.6 ± 2.64 |
| Chloride; EW; n= 3,3,7,3,11,11 | -1.0 ± 1.00 | 1.3 ± 1.53 | 0.3 ± 1.98 | 1.0 ± 2.00 | 0.1 ± 1.70 | 0.6 ± 2.66 |
| CO2; Week 2; n= 38,39,38,39,33,32 | -1.8 ± 2.04 | -0.8 ± 2.52 | -1.2 ± 2.30 | -0.4 ± 2.47 | -0.9 ± 2.39 | -1.0 ± 2.15 |
| CO2; Week 4; n= 38,39,38,38,30,32 | -1.4 ± 1.98 | -0.8 ± 3.07 | -1.3 ± 2.14 | -0.7 ± 2.22 | -0.5 ± 2.71 | -1.0 ± 2.06 |
| CO2; Week 8; n= 35,37,34,38,29,28 | -1.9 ± 2.34 | -1.1 ± 3.35 | -1.1 ± 2.21 | -0.7 ± 2.60 | -0.8 ± 2.43 | -1.8 ± 2.65 |
| CO2; Week 12; n=36,37,32,35,28,28 | -1.1 ± 2.12 | -1.0 ± 3.20 | -1.1 ± 2.45 | -0.7 ± 2.10 | -0.5 ± 2.49 | -1.1 ± 2.07 |
| CO2; Week 14; n=33,35,32,34,31,29 | -1.1 ± 2.23 | -0.8 ± 3.09 | -1.3 ± 2.59 | -0.6 ± 3.13 | -0.9 ± 2.29 | -1.3 ± 1.86 |
| CO2; EW; n=3,3,7,3,11,11 | 0.0 ± 1.00 | -0.3 ± 2.08 | -1.9 ± 3.18 | 0.3 ± 1.53 | 0.0 ± 2.19 | -0.4 ± 1.80 |
| Glucose; Week 2; n=38,39,38,39,33,32 | 0.55 ± 1.710 | 0.65 ± 1.384 | 0.13 ± 1.084 | 0.37 ± 1.431 | 0.46 ± 0.687 | -0.10 ± 3.059 |
| Glucose; Week 4; n= 38,39,38,38,30,32 | 0.53 ± 1.334 | 0.25 ± 1.101 | 0.02 ± 1.089 | 0.64 ± 1.209 | 0.38 ± 1.154 | -0.00 ± 3.164 |
| Glucose; Week 8; n=35,37,34,38,29,28 | 0.40 ± 1.450 | 0.42 ± 1.253 | 0.01 ± 0.942 | 0.51 ± 1.106 | 0.44 ± 1.048 | -0.34 ± 3.256 |
| Glucose; Week 12; n= 36,37,32,35,28,28 | 0.22 ± 1.664 | 0.16 ± 0.990 | 0.01 ± 1.097 | 0.36 ± 1.077 | 0.50 ± 1.028 | -0.49 ± 3.240 |
| Glucose; Week 14; n=33,35,32,34,31,29 | 0.29 ± 1.091 | 0.47 ± 1.275 | -0.14 ± 1.465 | 0.14 ± 1.482 | 0.12 ± 0.868 | -0.52 ± 3.871 |
| Glucose; EW; n= 3,3,7,3,11,11 | -0.30 ± 0.557 | -0.70 ± 0.889 | 0.67 ± 1.154 | -0.10 ± 2.007 | 0.32 ± 0.873 | 0.11 ± 0.997 |
| Potassium; Week 2; n= 38,39,38,39,33,32 | -0.06 ± 0.318 | 0.04 ± 0.360 | 0.04 ± 0.359 | 0.03 ± 0.381 | 0.08 ± 0.371 | 0.03 ± 0.339 |
| Potassium; Week 4; n= 38,39,38,38,30,32 | -0.02 ± 0.359 | 0.09 ± 0.446 | 0.19 ± 0.740 | 0.01 ± 0.337 | 0.04 ± 0.254 | 0.01 ± 0.428 |
| Potassium; Week 8; n= 35,37,34,38,29,28 | 0.05 ± 0.389 | 0.09 ± 0.303 | 0.19 ± 0.765 | 0.03 ± 0.316 | 0.04 ± 0.344 | -0.06 ± 0.370 |
| Potassium; Week 12; n= 36,37,32,35,28,28 | 0.04 ± 0.371 | 0.13 ± 0.335 | -0.01 ± 0.449 | -0.01 ± 0.339 | 0.06 ± 0.398 | 0.01 ± 0.403 |
| Potassium; Week 14; n=33,35,32,34,31,29 | 0.09 ± 0.309 | 0.13 ± 0.422 | 0.09 ± 0.570 | 0.03 ± 0.349 | 0.14 ± 0.503 | -0.00 ± 0.348 |
| Potassium; EW; n= 3,3,7,3,11,11 | -0.20 ± 0.100 | -0.13 ± 0.208 | 0.10 ± 0.252 | -0.37 ± 0.058 | -0.02 ± 0.236 | -0.00 ± 0.366 |
| Sodium; Week 2; n= 38,39,38,39,33,32 | -0.5 ± 2.19 | 0.1 ± 2.17 | -0.1 ± 2.33 | -0.3 ± 2.19 | -0.4 ± 1.90 | -0.2 ± 1.60 |
| Sodium; Week 4; n= 38,39,38,38,30,32 | -0.1 ± 2.16 | -0.5 ± 1.94 | -0.2 ± 1.78 | -0.9 ± 1.83 | -0.3 ± 2.14 | -0.1 ± 1.65 |
| Sodium; Week 8; n=35,37,34,38,29,28 | -0.3 ± 2.19 | -0.2 ± 2.75 | -0.2 ± 2.21 | -0.7 ± 1.94 | -0.6 ± 1.84 | -0.0 ± 2.50 |
| Sodium; Week 12; n=36,37,32,35,28,28 | -0.4 ± 2.11 | -0.4 ± 2.30 | -0.1 ± 2.06 | -0.8 ± 2.02 | -0.8 ± 2.14 | -0.3 ± 2.14 |
| Sodium; Week 14; n=33,35,32,34,31,29 | 0.2 ± 1.97 | -0.6 ± 1.75 | -0.2 ± 2.34 | -1.0 ± 2.00 | -0.7 ± 2.22 | -0.1 ± 1.93 |
| Sodium; EW; n=3,3,7,3,11,11 | -1.3 ± 1.15 | -1.3 ± 2.08 | -2.0 ± 1.00 | -0.3 ± 0.58 | 0.1 ± 1.58 | 0.5 ± 2.34 |
| BUN; Week 2; n= 38,39,38,39,33,32 | -0.38 ± 1.205 | -0.33 ± 1.078 | 0.03 ± 1.026 | 0.10 ± 1.001 | 0.29 ± 1.256 | -0.19 ± 1.098 |
| BUN; Week 4; n=38,39,38,38,30,32 | -0.38 ± 1.142 | -0.21 ± 1.276 | 0.00 ± 1.202 | -0.08 ± 1.094 | 0.10 ± 1.367 | -0.11 ± 1.091 |
| BUN; Week 8; n= 35,37,34,38,29,28 | -0.27 ± 1.251 | 0.08 ± 1.199 | -0.03 ± 0.807 | -0.18 ± 1.099 | 0.17 ± 1.159 | 0.02 ± 1.572 |
| BUN; Week 12; n= 36,37,32,35,28,28 | -0.38 ± 1.250 | -0.09 ± 1.767 | -0.05 ± 1.080 | 0.07 ± 1.030 | 0.23 ± 1.384 | 0.07 ± 1.614 |
| BUN; Week 14; n=33,35,32,34,31,29 | 0.02 ± 1.361 | 0.21 ± 1.540 | 0.19 ± 1.148 | 0.15 ± 1.209 | 0.02 ± 1.268 | 0.19 ± 1.429 |
| BUN; EW; n= 3,3,7,3,11,11 | -0.33 ± 0.577 | -0.50 ± 1.000 | -0.36 ± 1.144 | -1.00 ± 0.866 | 0.50 ± 0.775 | -0.23 ± 1.915 |
Blood samples were collected from participants for evaluation of clinical chemistry parameters by Potential Clinical Importance Criteria from Baseline to Week 14, EW and any visit post-screen. The vital signs included alk.phosph., ALT, AST, bilirubin, calcium, CO2, creatinine, glucose and potassium. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
| Participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Alk.Phosph;Baseline; n= 40,41,43,41,42,40 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alk.Phosph; Week 2; n= 38,39,38,39,33,32 | 1 | 0 | 0 | 0 | 0 | 0 |
| Alk.Phosph.; Week 4; n= 38,39, 38,38,30,32 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alk.Phosph.; Week 8; n= 35, 37, 34, 38, 29, 28 | 1 | 0 | 0 | 0 | 0 | 0 |
| Alk.Phosph.; Week 12; n= 36, 37, 32, 35, 28, 28 | 1 | 0 | 0 | 0 | 0 | 0 |
| Alk.Phosph.; Week 14; n= 33, 35, 32, 34, 31, 29 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alk.Phosph.; EW; n= 3, 3, 7, 3, 11, 11 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alk. Phosph.; post-screen; n= 40, 40,40,39,39,40 | 1 | 0 | 0 | 0 | 0 | 0 |
| ALT; Baseline; n= 40,41,43,41,42,40 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT; Week 2; n= 38,39,38,39,33,32 | 1 | 0 | 1 | 0 | 0 | 0 |
| ALT; Week 4; n= 38,39, 38,38,30,32 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT; Week 8; n=35, 37, 34, 38, 29, 28 | 1 | 0 | 0 | 0 | 0 | 0 |
| ALT; Week 12; n= 36, 37, 32, 35, 28, 28 | 1 | 0 | 0 | 0 | 0 | 0 |
| ALT; Week 14; n=33, 35, 32, 34, 31, 29 | 1 | 0 | 0 | 0 | 0 | 0 |
| ALT; EW; n= 3, 3, 7, 3, 11, 11 | 0 | 0 | 1 | 0 | 0 | 0 |
| ALT; post-screen; n= 40, 40,40,39,39,40 | 2 | 0 | 2 | 0 | 0 | 0 |
| AST; Baseline; n= 40,41,43,41,42,40 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST; Week 2; n=38,39,38,39,33,32 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST; Week 4; n= 38,39, 38,38,30,32 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST; Week 8; n= 35, 37, 34, 38, 29, 28 | 2 | 0 | 0 | 0 | 0 | 0 |
| AST; Week 12; n= 36, 37, 32, 35, 28, 28 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST; Week 14; n= 33, 35, 32, 34, 31, 29 | 2 | 0 | 0 | 0 | 0 | 0 |
| AST; EW; n= 3, 3, 7, 3, 11, 11 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST; Post-screen; n= 40, 40,40,39,39,40 | 4 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin; Baseline; n= 40,41,43,41,42,40 | 0 | 0 | 0 | 0 | 1 | 0 |
| Bilirubin; Week 2; n= 38,39,38,39,33,32 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin; Week 4; n= 38,39, 38,38,30,32 | 0 | 0 | 0 | 0 | 0 | 1 |
| Bilirubin; Week 8; n= 35, 37, 34, 38, 29, 28 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin; Week 12; n=36, 37, 32, 35, 28, 28 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin; Week 14; n= 33, 35, 32, 34, 31, 29 | 0 | 0 | 1 | 0 | 0 | 0 |
| Bilirubin; EW; n= 3, 3, 7, 3, 11, 11 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin; post-screen; n= 40, 40,40,39,39,40 | 0 | 0 | 1 | 0 | 0 | 1 |
| Calcium; Baseline; n= 40,41,43,41,42,40 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium; Week 2; n=38,39,38,39,33,32 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium; Week 4; n= 38,39, 38,38,30,32 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium; Week 8; n= 35, 37, 34, 38, 29, 28 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium; Week 12; n= 36, 37, 32, 35, 28, 28 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium; Week 14; n= 33, 35, 32, 34, 31, 29 | 0 | 0 | 1 | 0 | 0 | 0 |
| Calcium; EW; n= 3, 3, 7, 3, 11, 11 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium; post-screen; n= 40, 40,40,39,39,40 | 0 | 0 | 1 | 0 | 0 | 0 |
| CO2; Baseline; n= 40,41,43,41,42,40 | 0 | 1 | 0 | 1 | 0 | 0 |
| CO2; Week 2; n=38,39,38,39,33,32 | 1 | 1 | 1 | 0 | 0 | 1 |
| CO2; Week 4; n= 38,39, 38,38,30,32 | 0 | 0 | 1 | 0 | 0 | 0 |
| CO2; Week 8; n= 35, 37, 34, 38, 29, 28 | 1 | 1 | 0 | 1 | 0 | 2 |
| CO2; Week 12; n= 36, 37, 32, 35, 28, 28 | 0 | 0 | 0 | 1 | 0 | 0 |
| CO2; Week 14; n= 33, 35, 32, 34, 31, 29 | 1 | 0 | 2 | 1 | 1 | 0 |
| CO2; EW; n= 3, 3, 7, 3, 11, 11 | 0 | 0 | 0 | 0 | 0 | 0 |
| CO2; Post-screen; n= 40, 40,40,39,39,40 | 3 | 2 | 4 | 3 | 1 | 3 |
| Creatinine; Baseline; n= 40,41,43,41,42,40 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine; Week 2; n= 38,39,38,39,33,32 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine; Week 4; n= 38,39, 38,38,30,32 | 0 | 0 | 0 | 0 | 0 | 1 |
| Creatinine; Week 8; n= 35, 37, 34, 38, 29, 28 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine; Week 12; n= 36, 37, 32, 35, 28, 28 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine; Week 14; n= 33, 35, 32, 34, 31, 29 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine; EW; n= 3, 3, 7, 3, 11, 11 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine; post-screen; n= 40, 40,40,39,39,40 | 0 | 0 | 0 | 0 | 0 | 1 |
| Glucose; Baseline; n= 40,41,43,41,42,40 | 0 | 1 | 2 | 2 | 1 | 2 |
| Glucose; Week 2; n= 38,39,38,39,33,32 | 2 | 2 | 0 | 3 | 0 | 2 |
| Glucose; Week 4; n= 38,39, 38,38,30,32 | 1 | 1 | 0 | 2 | 0 | 3 |
| Glucose; Week 8; n=35, 37, 34, 38, 29, 28 | 1 | 2 | 1 | 2 | 0 | 2 |
| Glucose; Week 12; n= 36, 37, 32, 35, 28, 28 | 2 | 1 | 1 | 1 | 0 | 2 |
| Glucose; Week 14; n= 33, 35, 32, 34, 31, 29 | 0 | 2 | 0 | 3 | 0 | 1 |
| Glucose; EW; n= 3, 3, 7, 3, 11, 11 | 0 | 0 | 0 | 1 | 0 | 0 |
| Glucose; post-screen; n= 40, 40,40,39,39,40 | 4 | 4 | 1 | 6 | 0 | 5 |
| Potassium; Baseline; n= 40,41,43,41,42,40 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium; Week 2; n= 38,39,38,39,33,32 | 0 | 0 | 0 | 1 | 1 | 0 |
| Potassium; Week 4; n= 38,39, 38,38,30,32 | 0 | 0 | 2 | 0 | 0 | 0 |
| Potassium; Week 8; n= 35, 37, 34, 38, 29, 28 | 0 | 0 | 1 | 0 | 0 | 0 |
| Potassium; n= Week 12; n= 36, 37, 32, 35, 28, 28 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium; Week 14; n= 33, 35, 32, 34, 31, 29 | 0 | 0 | 1 | 0 | 1 | 0 |
| Potassium;EW; n= 3, 3, 7, 3, 11, 11 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium; post-screen; n= 40, 40,40,39,39,40 | 0 | 0 | 2 | 1 | 1 | 0 |
Blood samples were collected to evaluate change from Baseline in basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet and leukocytes and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
| Giga cells per liter (GI/L) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Basophils; Week 2; n= 37,38,38,37,33,31 | -0.006 ± 0.0177 | -0.001 ± 0.0205 | -0.000 ± 0.0201 | -0.002 ± 0.0175 | -0.004 ± 0.0166 | 0.000 ± 0.0176 |
| Basophils; Week 4; n= 38,38,38,37,30,31 | -0.002 ± 0.0195 | 0.000 ± 0.0201 | 0.005 ± 0.0241 | -0.000 ± 0.0191 | -0.006 ± 0.0192 | 0.006 ± 0.0218 |
| Basophils; Week 8; n= 34,36,34,37,29,27 | -0.004 ± 0.0224 | -0.001 ± 0.0214 | 0.000 ± 0.0165 | -0.007 ± 0.0161 | -0.005 ± 0.0218 | 0.004 ± 0.0162 |
| Basophils; Week 12; n= 36,36,32,34,28,27 | 0.001 ± 0.0166 | 0.002 ± 0.0191 | 0.005 ± 0.0244 | 0.003 ± 0.0343 | 0.003 ± 0.0348 | 0.010 ± 0.0236 |
| Basophils; Week 14; n= 33,33,32,32,31,27 | -0.001 ± 0.0160 | -0.000 ± 0.0190 | 0.003 ± 0.0202 | -0.003 ± 0.0226 | 0.008 ± 0.0312 | -0.001 ± 0.0188 |
| Basophils; EW; n= 3,3,7,3,10,10 | -0.000 ± 0.0173 | 0.020 ± 0.0100 | 0.007 ± 0.0180 | 0.017 ± 0.0115 | 0.011 ± 0.0110 | -0.005 ± 0.0264 |
| Eosinophils; Week 2; n=37,38,38,37,33,31 | -0.035 ± 0.2153 | 0.012 ± 0.1629 | -0.092 ± 0.2733 | -0.018 ± 0.2325 | 0.064 ± 0.4397 | 0.052 ± 0.1474 |
| Eosinophils; Week 4; n=38,38,38,37,30,31 | -0.075 ± 0.3146 | -0.049 ± 0.2401 | -0.119 ± 0.3926 | -0.034 ± 0.2143 | 0.063 ± 0.4729 | 0.057 ± 0.1644 |
| Eosinophils; Week 8; n=34,36,34,37,29,27 | -0.052 ± 0.3486 | -0.040 ± 0.1398 | -0.107 ± 0.3276 | -0.034 ± 0.2271 | 0.009 ± 0.1923 | 0.106 ± 0.2805 |
| Eosinophils; Week 12; n= 36,36,32,34,28,27 | -0.083 ± 0.3212 | -0.026 ± 0.1811 | -0.120 ± 0.3025 | -0.063 ± 0.1751 | -0.028 ± 0.2176 | 0.033 ± 0.1606 |
| Eosinophils; Week 14; n= 33,33,32,32,31,27 | -0.078 ± 0.3178 | -0.043 ± 0.2237 | -0.104 ± 0.2377 | -0.056 ± 0.1493 | -0.041 ± 0.2107 | 0.038 ± 0.1779 |
| Eosinophils; EW; n=3,3,7,3,10,10 | 0.113 ± 0.1501 | 0.117 ± 0.1680 | -0.220 ± 0.3114 | 0.047 ± 0.0643 | 0.065 ± 0.1905 | 0.062 ± 0.3301 |
| Lymphocytes; Week 2; n= 37,38,38,37,33,31 | 0.035 ± 0.4672 | 0.076 ± 0.5239 | 0.123 ± 0.5263 | 0.064 ± 0.3510 | 0.030 ± 0.4724 | 0.018 ± 0.4654 |
| Lymphocytes; Week 4; n= 38,38,38,37,30,31 | 0.054 ± 0.5264 | 0.217 ± 0.5292 | 0.083 ± 0.5894 | 0.021 ± 0.4099 | -0.078 ± 0.4874 | 0.151 ± 0.5349 |
| Lymphocytes; Week 8; n= 34,36,34,37,29,27 | 0.100 ± 0.3953 | 0.165 ± 0.6213 | 0.012 ± 0.4463 | -0.031 ± 0.3914 | -0.018 ± 0.5285 | 0.166 ± 0.4024 |
| Lymphocytes; Week 12; n= 36,36,32,34,28,27 | 0.045 ± 0.4806 | 0.232 ± 0.6258 | 0.061 ± 0.5758 | 0.072 ± 0.4836 | -0.034 ± 0.5779 | 0.116 ± 0.3819 |
| Lymphocytes; Week 14; n= 33,33,32,32,31,27 | 0.030 ± 0.4869 | 0.146 ± 0.5891 | -0.093 ± 0.6048 | 0.195 ± 0.5632 | -0.035 ± 0.5757 | 0.184 ± 0.3451 |
| Lymphocytes; EW; n= 3,3,7,3,10,10 | -0.317 ± 0.5315 | 0.040 ± 0.0954 | -0.136 ± 0.4644 | 0.450 ± 0.0755 | -0.021 ± 0.4694 | -0.225 ± 0.4165 |
| Monocytes; Week 2; n=37,38,38,37,33,31 | -0.028 ± 0.1465 | -0.025 ± 0.1271 | 0.013 ± 0.1659 | 0.008 ± 0.0965 | -0.028 ± 0.1415 | 0.019 ± 0.1948 |
| Monocytes; Week 4; n= 38,38,38,37,30,31 | -0.004 ± 0.1769 | -0.023 ± 0.1230 | -0.059 ± 0.1648 | 0.006 ± 0.1151 | -0.047 ± 0.1611 | 0.010 ± 0.1419 |
| Monocytes; Week 8; n= 34,36,34,37,29,27 | -0.071 ± 0.1443 | -0.041 ± 0.1224 | -0.032 ± 0.1355 | -0.012 ± 0.1359 | -0.066 ± 0.1465 | -0.001 ± 0.1171 |
| Monocytes; Week 12; n=36,36,32,34,28,27 | -0.061 ± 0.1653 | -0.022 ± 0.1219 | -0.042 ± 0.1539 | -0.019 ± 0.1434 | -0.078 ± 0.1736 | 0.007 ± 0.1801 |
| Monocytes; Week 14; n=33,33,32,32,31,27 | -0.026 ± 0.1532 | 0.027 ± 0.1427 | -0.016 ± 0.1446 | 0.015 ± 0.1666 | -0.093 ± 0.1497 | 0.035 ± 0.1821 |
| Monocytes; EW; n=3,3,7,3,10,10 | -0.127 ± 0.0924 | 0.007 ± 0.0850 | 0.030 ± 0.1133 | 0.040 ± 0.0608 | -0.018 ± 0.0966 | -0.159 ± 0.1672 |
| Neutrophils; Week 2; n=37,38,38,37,33,31 | 0.480 ± 1.7953 | 0.152 ± 1.0058 | 0.067 ± 1.7035 | -0.088 ± 1.4680 | -0.097 ± 1.8249 | -0.258 ± 1.2803 |
| Neutrophils; Week 4; n=38,38,38,37,30,31 | 0.487 ± 2.0425 | 0.253 ± 1.1437 | -0.058 ± 1.7028 | 0.035 ± 1.3063 | -0.141 ± 2.1024 | 0.100 ± 1.4283 |
| Neutrophils; Week 8; n= 34,36,34,37,29,27 | 0.009 ± 1.4215 | -0.203 ± 1.0365 | -0.083 ± 1.4454 | 0.550 ± 1.5918 | -0.432 ± 1.5971 | 0.214 ± 1.1894 |
| Neutrophils; Week 12; n= 36,36,32,34,28,27 | 0.127 ± 1.3363 | -0.009 ± 1.1315 | 0.049 ± 1.4294 | 0.237 ± 1.1459 | -0.348 ± 1.5514 | 0.328 ± 1.6786 |
| Neutrophils; Week 14; n=33,33,32,32,31,27 | 0.090 ± 1.2037 | 0.164 ± 1.2465 | -0.368 ± 1.0224 | -0.058 ± 1.5202 | -0.155 ± 1.9840 | -0.013 ± 1.4826 |
| Neutrophils; EW; n=3,3,7,3,10,10 | -0.420 ± 0.9924 | 0.047 ± 0.7478 | 0.797 ± 2.1506 | 0.630 ± 1.0741 | -0.331 ± 1.2306 | 0.158 ± 1.8160 |
| Platelet; Week 2; n=37,38,38,37,33,31 | -15.4 ± 44.06 | -18.7 ± 36.48 | -25.9 ± 43.03 | -20.2 ± 30.63 | -0.5 ± 31.18 | 6.9 ± 31.60 |
| Platelet; Week 4; n=38,38,38,37,30,31 | -12.4 ± 36.57 | -19.7 ± 36.44 | -25.2 ± 35.75 | -7.7 ± 38.40 | -2.4 ± 30.48 | 12.7 ± 29.38 |
| Platelet; Week 8; n= 34,36,34,37,29,27 | -6.2 ± 34.81 | -9.1 ± 51.69 | -22.1 ± 37.57 | -11.5 ± 44.80 | 1.4 ± 37.70 | 8.8 ± 39.83 |
| Platelet; Week 12; n=36,36,32,34,28,27 | -7.5 ± 37.94 | -5.4 ± 30.15 | -23.6 ± 38.11 | -18.9 ± 38.67 | -4.6 ± 35.71 | -6.8 ± 24.06 |
| Platelet; Week 14; n=33,33,32,32,31,27 | 3.5 ± 40.84 | -9.0 ± 38.20 | -19.9 ± 44.95 | -8.2 ± 47.60 | 5.1 ± 31.34 | 6.5 ± 51.77 |
| Platelet; EW; n=3,3,7,3,10,10 | -85.0 ± 11.00 | 12.7 ± 56.01 | -19.7 ± 25.77 | 11.7 ± 18.56 | 8.4 ± 24.56 | 11.3 ± 59.83 |
| Leukocytes; Week 2; n=37,38,38,37,33,31 | 0.45 ± 1.749 | 0.21 ± 1.085 | 0.10 ± 1.668 | -0.02 ± 1.585 | -0.05 ± 1.972 | -0.16 ± 1.624 |
| Leukocytes; Week 4; n= 38,38,38,37,30,31 | 0.46 ± 1.913 | 0.40 ± 1.232 | -0.15 ± 1.807 | 0.03 ± 1.517 | -0.21 ± 2.221 | 0.34 ± 1.694 |
| Leukocytes; Week 8; n=34,36,34,37,29,27 | 0.03 ± 1.466 | -0.12 ± 1.257 | -0.21 ± 1.567 | 0.47 ± 1.469 | -0.52 ± 1.721 | 0.49 ± 1.113 |
| Leukocytes; Week 12; n=36,36,32,34,28,27 | 0.03 ± 1.488 | 0.18 ± 1.249 | -0.05 ± 1.371 | 0.23 ± 1.248 | -0.49 ± 1.456 | 0.49 ± 1.776 |
| Leukocytes; Week 14; n=33,33,32,32,31,27 | 0.02 ± 1.234 | 0.30 ± 1.200 | -0.57 ± 1.142 | 0.10 ± 1.705 | -0.32 ± 2.121 | 0.23 ± 1.498 |
| Leukocytes; EW; n= 3,3,7,3,10,10 | -0.73 ± 0.666 | 0.23 ± 1.115 | 0.47 ± 2.394 | 1.20 ± 1.127 | -0.29 ± 1.454 | -0.16 ± 2.151 |
Blood samples were collected to evaluate change from Baseline in hematocrit and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
| Proportion of red blood cells in blood | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 2; n= 37,38,38,37,33,31 | -0.0054 ± 0.0276 | -0.0132 ± 0.0195 | -0.0138 ± 0.0260 | -0.0116 ± 0.0246 | -0.0014 ± 0.0267 | -0.0095 ± 0.0239 |
| Week 4; n= 38,38,38,37,30,31 | -0.0107 ± 0.0315 | -0.0075 ± 0.0241 | -0.0081 ± 0.0253 | -0.0075 ± 0.0233 | -0.0090 ± 0.0283 | -0.0123 ± 0.0295 |
| Week 8; n=34,36,34,37,29,27 | -0.0066 ± 0.0316 | -0.0148 ± 0.0225 | -0.0091 ± 0.0225 | -0.0042 ± 0.0235 | -0.0011 ± 0.0264 | -0.0124 ± 0.0314 |
| Week 12; n= 36,36,32,34,28,27 | -0.0054 ± 0.0302 | -0.0129 ± 0.0222 | -0.0131 ± 0.0205 | -0.0106 ± 0.0227 | -0.0052 ± 0.0312 | -0.0111 ± 0.0240 |
| Week 14; n= 33,33,32,32,31,28 | -0.0151 ± 0.0292 | -0.0170 ± 0.0236 | -0.0132 ± 0.0193 | -0.0063 ± 0.0286 | -0.0007 ± 0.0277 | -0.0117 ± 0.0292 |
| EW; n= 3,3,7,3,10,10 | 0.0037 ± 0.0123 | -0.0063 ± 0.0352 | -0.0174 ± 0.0292 | -0.0117 ± 0.0133 | 0.0027 ± 0.0152 | 0.0048 ± 0.0248 |
Blood samples were collected to evaluate change from Baseline in hemoglobin and MCHC and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
| G/L | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Hemoglobin; Week 2; n= 37,38,38,37,33,31 | -1.8 ± 9.02 | -3.8 ± 5.54 | -4.3 ± 8.08 | -2.8 ± 6.78 | -0.9 ± 8.76 | -3.0 ± 6.55 |
| Hemoglobin; Week 4; n= 38,38,38,37,30,31 | -3.2 ± 8.88 | -2.7 ± 6.42 | -3.5 ± 7.72 | -2.4 ± 6.27 | -3.0 ± 9.17 | -4.1 ± 9.05 |
| Hemoglobin; Week 8; n=34,36,34,37,29,27 | -2.7 ± 9.64 | -4.6 ± 6.43 | -3.7 ± 6.90 | -1.6 ± 6.70 | -0.8 ± 7.59 | -4.6 ± 9.72 |
| Hemoglobin; Week 12; n= 36,36,32,34,28,27 | -2.3 ± 9.33 | -4.2 ± 6.61 | -5.2 ± 6.77 | -3.1 ± 5.58 | -2.5 ± 9.52 | -4.4 ± 6.63 |
| Hemoglobin; Week 14; n= 33,33,32,32,31,28 | -5.5 ± 9.25 | -3.9 ± 6.76 | -5.2 ± 6.73 | -1.8 ± 8.17 | -0.8 ± 8.51 | -4.0 ± 7.93 |
| Hemoglobin; EW; n= 3,3,7,3,10,10 | 0.7 ± 11.59 | -1.3 ± 11.59 | -6.0 ± 8.47 | -2.0 ± 9.00 | 0.0 ± 3.77 | -1.1 ± 5.69 |
| MCHC; Week 2; n= 37,38,38,37,33,31 | 0.1 ± 7.47 | 0.9 ± 7.83 | 0.8 ± 6.65 | 2.0 ± 10.23 | -1.4 ± 8.37 | 8.37 ± 8.92 |
| MCHC; Week 4; n= 38,38,38,37,30,31 | 0.9 ± 8.89 | -0.3 ± 9.51 | -1.9 ± 9.53 | 0.2 ± 9.62 | 0.0 ± 9.14 | 0.1 ± 8.17 |
| MCHC; Week 8; n=34,36,34,37,29,27 | -1.1 ± 9.28 | 0.4 ± 11.61 | -1.9 ± 8.69 | -0.5 ± 11.02 | -0.5 ± 10.28 | -1.3 ± 8.96 |
| MCHC; Week 12; n= 36,36,32,34,28,27 | -1.0 ± 10.23 | 0.1 ± 11.12 | -2.5 ± 10.95 | 0.9 ± 10.85 | -1.4 ± 10.77 | -1.8 ± 9.95 |
| MCHC; Week 14; n= 33,33,32,32,31,28 | -1.2 ± 11.15 | 3.9 ± 10.96 | -2.2 ± 10.24 | 0.7 ± 10.42 | -1.0 ± 11.18 | -0.1 ± 8.59 |
| MCHC; EW; n= 3,3,7,3,10,10 | -1.7 ± 20.26 | 1.7 ± 2.52 | -1.1 ± 10.64 | 3.3 ± 12.86 | -2.2 ± 5.25 | -6.6 ± 9.09 |
Blood samples were collected to evaluate change from Baseline in MCH and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
| Picogram (Pg) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 2; n= 37,38,38,37,33,31 | 0.05 ± 0.425 | 0.09 ± 0.595 | 0.06 ± 0.408 | 0.19 ± 0.667 | 0.04 ± 0.415 | 0.05 ± 0.490 |
| Week 4; n= 38,38,38,37,30,31 | 0.09 ± 0.535 | 0.06 ± 0.593 | -0.01 ± 0.519 | 0.15 ± 0.567 | 0.06 ± 0.518 | -0.05 ± 0.528 |
| Week 8; n=34,36,34,37,29,27 | 0.03 ± 0.635 | 0.21 ± 0.747 | -0.06 ± 0.536 | 0.22 ± 0.781 | 0.02 ± 0.599 | -0.07 ± 0.640 |
| Week 12; n= 36,36,32,34,28,27 | 0.14 ± 0.708 | 0.14 ± 0.790 | 0.10 ± 0.506 | 0.30 ± 0.815 | 0.04 ± 0.588 | 0.06 ± 0.806 |
| Week 14; n= 33,33,32,32,31,28 | 0.06 ± 0.900 | 0.55 ± 0.806 | 0.08 ± 0.449 | 0.28 ± 0.612 | 0.06 ± 0.804 | -0.01 ± 0.589 |
| EW; n= 3,3,7,3,10,10 | 0.57 ± 1.361 | 0.03 ± 0.702 | -0.19 ± 0.596 | 0.63 ± 0.808 | -0.13 ± 0.933 | -0.15 ± 0.542 |
Blood samples were collected to evaluate change from Baseline in MCV and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
| Femtoliter (fL) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 2; n= 37,38,38,37,33,31 | 0.2 ± 2.02 | -0.2 ± 1.45 | -0.1 ± 1.47 | -0.1 ± 2.37 | 0.5 ± 1.87 | 0.1 ± 1.83 |
| Week 4; n= 38,38,38,37,30,31 | 0.1 ± 1.75 | 0.2 ± 2.04 | 0.5 ± 1.94 | 0.4 ± 2.80 | 0.1 ± 1.90 | -0.3 ± 1.85 |
| Week 8; n=34,36,34,37,29,27 | 0.5 ± 2.42 | 0.5 ± 2.52 | 0.4 ± 1.78 | 0.7 ± 2.90 | 0.2 ± 2.39 | 0.0 ± 2.01 |
| Week 12; n= 36,36,32,34,28,27 | 0.8 ± 2.80 | 0.3 ± 2.68 | 1.0 ± 2.62 | 0.6 ± 3.20 | 0.5 ± 3.06 | 0.5 ± 1.99 |
| Week 14; n= 33,33,32,32,31,28 | 0.6 ± 2.92 | 0.4 ± 2.54 | 0.9 ± 2.54 | 0.7 ± 2.37 | 0.4 ± 3.19 | -0.1 ± 2.25 |
| EW; n= 3,3,7,3,10,10 | 1.7 ± 1.53 | -0.7 ± 2.08 | -0.4 ± 2.15 | 1.0 ± 1.00 | -0.1 ± 2.81 | 1.4 ± 2.59 |
Blood samples were collected to evaluate change from Baseline in erythrocytes and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
| Tetra cells per liter (TI/L) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 2; n= 37,38,38,37,33,31 | -0.06 ± 0.325 | -0.16 ± 0.218 | -0.15 ± 0.287 | -0.12 ± 0.260 | -0.03 ± 0.293 | -0.12 ± 0.241 |
| Week 4; n= 38,38,38,37,30,31 | -0.12 ± 0.347 | -0.10 ± 0.256 | -0.13 ± 0.273 | -0.10 ± 0.215 | -0.11 ± 0.317 | -0.13 ± 0.312 |
| Week 8; n=34,36,34,37,29,27 | -0.10 ± 0.371 | -0.21 ± 0.227 | -0.12 ± 0.265 | -0.08 ± 0.205 | -0.03 ± 0.268 | -0.14 ± 0.318 |
| Week 12; n= 36,36,32,34,28,27 | -0.09 ± 0.345 | -0.18 ± 0.244 | -0.21 ± 0.250 | -0.15 ± 0.191 | -0.09 ± 0.314 | -0.15 ± 0.262 |
| Week 14; n= 33,33,32,32,31,28 | -0.20 ± 0.342 | -0.22 ± 0.262 | -0.21 ± 0.229 | -0.10 ± 0.261 | -0.03 ± 0.330 | -0.14 ± 0.312 |
| EW; n= 3,3,7,3,10,10 | -0.03 ± 0.252 | -0.07 ± 0.321 | -0.19 ± 0.297 | -0.13 ± 0.153 | 0.04 ± 0.246 | -0.03 ± 0.267 |
Blood samples were collected from participants for evaluation of hematology parameters by Potential Clinical Importance Criteria from Baseline to Week 14, EW and any visit post-screen. The vital signs included hematocrit, hemoglobin, lymphocytes, neutrophils, platelet and leukocytes. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
| Participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Hematocrit; Baseline; n= 40, 40, 43, 40, 42, 39 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hematocrit; Week 2; n= 37, 39, 38, 38, 33, 31 | 0 | 0 | 0 | 0 | 1 | 0 |
| Hematocrit; Week 4; n= 38, 39, 38,38,30,32 | 0 | 0 | 0 | 0 | 0 | 1 |
| Hematocrit; Week 8; n=34,36,34,38,29,28 | 1 | 0 | 1 | 0 | 1 | 1 |
| Hematocrit; Week 12; n= 36, 37, 32, 35, 28,28 | 1 | 0 | 0 | 0 | 0 | 0 |
| Hematocrit; Week 14; n= 33,34,32,33,31,29 | 1 | 0 | 0 | 0 | 0 | 2 |
| Hematocrit; EW; n= 3,3,7,3,10,10 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hematocrit; post-screen; n= 40,40,40,39,39,40 | 2 | 0 | 1 | 0 | 1 | 2 |
| Hemoglobin; Baseline;n= 40, 40, 43, 40, 42, 39 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin; Week 2; n= 37, 39, 38, 38, 33, 31 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin; Week 4; n= 38, 39, 38,38,30,32 | 0 | 0 | 0 | 0 | 0 | 1 |
| Hemoglobin; Week 8; n= 34,36,34,38,29,28 | 1 | 0 | 0 | 0 | 0 | 1 |
| Hemoglobin; Week 12; n= 36, 37, 32, 35, 28,28 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin; Week 14; n=33,34,32,33,31,29 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin; EW; n= 3,3,7,3,10,10 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin; post-screen; n= 40,40,40,39,39,40 | 1 | 0 | 0 | 0 | 0 | 1 |
| Lymphocytes;Baseline; n= 40, 40, 43, 40, 42, 39 | 0 | 1 | 1 | 0 | 0 | 1 |
| Lymphocytes; Week 2; n= 37, 39, 38, 38, 33, 31 | 0 | 1 | 0 | 0 | 0 | 0 |
| Lymhocytes; Week 4; n= 38, 39, 38,38,30,32 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes; Week 8; n= 34,36,34,38,29,28 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes; Week 12; n=36, 37, 32, 35, 28,28 | 0 | 0 | 0 | 0 | 1 | 0 |
| Lymphocytes; Week 14; n= 33,34,32,33,31,28 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes; EW;n= 3,3,7,3,10,10 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes; post-screen; n= 40,40,40,39,39,40 | 0 | 1 | 0 | 0 | 1 | 0 |
| Neutrophils; Baseline; n= 40, 40, 43, 40, 42, 39 | 2 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils; Week 2; n= 37, 39, 38, 38, 33, 31 | 0 | 1 | 0 | 1 | 0 | 0 |
| Neutrophils; Week 4; n= 38, 39, 38,38,30,32 | 4 | 0 | 1 | 0 | 0 | 0 |
| Neutrophils; Week 8; n= 34,36,34,38,29,28 | 0 | 1 | 0 | 0 | 0 | 0 |
| Neutrophils; Week 12; n= 36, 37, 32, 35, 28,28 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils; Week 14; n=33,34,32,33,31,29 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils; EW; n=3,3,7,3,10,10 | 0 | 1 | 0 | 0 | 0 | 0 |
| Neutrophils; post-screen;n= 40,40,40,39,39,40 | 4 | 2 | 1 | 1 | 0 | 0 |
| Platelets; Baseline; n= 40, 40, 43, 40, 42, 39 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets; Week 2; n= :37,38,38,38,33,31 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets; Week 4; n=37,39, 38,38,30,32 | 0 | 0 | 0 | 0 | 1 | 0 |
| Platelets; Week 8; n= 34,36,34,38,29,28 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets; Week 12; n= 35,37,32,35,28,28 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets; Week 14; n=33,34,32,33,31,29 | 0 | 0 | 0 | 0 | 0 | 1 |
| Platelets; EW; n=3,3,7,3,10,10 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets; post-screen; n= 40,40,40,39,39,40 | 0 | 0 | 0 | 0 | 1 | 1 |
| Leukocytes; Baseline; n= 40, 40, 43, 40, 42, 39 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytes; Week 2; n=37, 39, 38, 38, 33, 31 | 0 | 1 | 0 | 1 | 0 | 0 |
| Leukocytes; Week 4; n=38, 39, 38,38,30,32 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytes; Week 8; n=34,36,34,38,29,28 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytes; Week 12; n= 36, 37, 32, 35, 28,28 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytes; Week 14; n=33,34,32,33,31,28 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytes; n= EW; n=3,3,7,3,10,10 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytes; post-screen; n= 40,40,40,39,39,40 | 0 | 1 | 0 | 1 | 0 | 0 |
Blood samples were collected to evaluate change from Baseline in total T lympho, B lympho, T and B NK cells and (Foxp3) values at Baseline throughout the 12 weeks of study treatment. The immunophenotyping parameters included cluster of differentiation (CD)19, CD3, CD3+CD8+, CD3+CD4+, CD16+CD56+, CD3+CD4+CD25+CD127, CD3+CD4+foxP3+CD25+CD127 and T and NK lympho. CD3, CD3+CD8+ and CD3+CD4+ were also evaluated by using treg flow cytometry (cyto). Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
| GI/L | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| CD19; Week 4; n= 37,38,38,37,29,32 | 0.0394 ± 0.1149 | 0.0407 ± 0.1229 | 0.0068 ± 0.1532 | 0.0174 ± 0.0933 | -0.0217 ± 0.1410 | 0.0406 ± 0.1114 |
| CD19; Week 8; n=34,37,34,37,28,27 | 0.0273 ± 0.0951 | 0.0343 ± 0.1480 | 0.0122 ± 0.1154 | -0.0006 ± 0.1099 | -0.0282 ± 0.1502 | 0.0367 ± 0.0966 |
| CD19; Week 12; n= 35,37,32,34,27,27 | 0.0111 ± 0.1262 | 0.0647 ± 0.1440 | 0.0317 ± 0.1077 | 0.0224 ± 0.0927 | -0.0439 ± 0.1350 | 0.0041 ± 0.1009 |
| CD3; Week 4; n= 37,38,38,37,29,32 | -0.0050 ± 0.3830 | 0.0867 ± 0.3809 | 0.0842 ± 0.3343 | 0.0108 ± 0.3364 | -0.0397 ± 0.4505 | 0.1678 ± 0.3583 |
| CD3; Week 8; n=34,37,34,37,28,27 | 0.0523 ± 0.3117 | 0.0581 ± 0.4496 | 0.0334 ± 0.3855 | -0.0593 ± 0.3172 | -0.0350 ± 0.4403 | 0.1066 ± 0.3531 |
| CD3; Week 12; n= 35,37,32,34,27,27 | -0.0045 ± 0.4254 | 0.1312 ± 0.4033 | 0.1375 ± 0.4003 | 0.0071 ± 0.2729 | -0.1338 ± 0.5023 | 0.0167 ± 0.2879 |
| CD3 treg flow cyto; Week 4; n= 35,37,36,35,28,28 | -0.0277 ± 0.3912 | 0.0643 ± 0.3988 | 0.0682 ± 0.2853 | 0.0270 ± 0.3320 | -0.0688 ± 0.4764 | 0.1943 ± 0.3722 |
| CD3; treg flow cyto; Week 8; n=31,35,32,36,27,25 | 0.0184 ± 0.2929 | 0.0745 ± 0.4592 | -0.0023 ± 0.3513 | -0.0647 ± 0.3128 | -0.0626 ± 0.4679 | 0.1302 ± 0.3505 |
| CD3; treg flow cyto; Week 12; n= 32,36,31,32,25,24 | -0.0215 ± 0.4120 | 0.1418 ± 0.4318 | 0.1171 ± 0.4070 | -0.0063 ± 0.2771 | -0.1402 ± 0.5450 | 0.0028 ± 0.3101 |
| CD3+CD8+; Week 4; n= 37,38,38,37,29,32 | -0.0272 ± 0.2077 | 0.0248 ± 0.1298 | 0.0282 ± 0.1266 | 0.0147 ± 0.1194 | -0.0155 ± 0.1608 | 0.0526 ± 0.1388 |
| CD3+CD8+; Week 8; n= 34,37,34,37,28,27 | -0.0048 ± 0.1337 | 0.0011 ± 0.1561 | 0.0242 ± 0.1335 | -0.0263 ± 0.1145 | -0.0315 ± 0.1677 | 0.0322 ± 0.1721 |
| CD3+CD8+; Week 12;n=35,37,32,34,27,27 | -0.0307 ± 0.1754 | 0.0270 ± 0.1392 | 0.0357 ± 0.1578 | -0.0115 ± 0.0868 | -0.0853 ± 0.1818 | -0.0023 ± 0.1097 |
| CD3+CD8+ treg flow cyto;Week 4;n=35,37,36,35,28,28 | -0.0392 ± 0.2124 | 0.0211 ± 0.1222 | 0.0004 ± 0.1117 | 0.0038 ± 0.1112 | -0.0246 ± 0.1572 | 0.0728 ± 0.1175 |
| CD3+CD8+ treg flow cyto;Week 8;n=31,35,32,36,27,25 | 0.0004 ± 0.1228 | 0.0125 ± 0.1350 | -0.0008 ± 0.1214 | -0.0376 ± 0.1150 | -0.0351 ± 0.1672 | 0.0484 ± 0.1417 |
| CD3+CD8+treg flow cyto;Week12;n=32,36,31,32,25,24 | -0.0179 ± 0.1738 | 0.0311 ± 0.1338 | 0.0151 ± 0.1490 | -0.0230 ± 0.0865 | -0.0689 ± 0.1752 | 0.0120 ± 0.1064 |
| CD3+CD4+; Week 4; n= 37,38,38,37,29,32 | 0.0080 ± 0.2066 | 0.0579 ± 0.2532 | 0.0562 ± 0.2652 | -0.0030 ± 0.2342 | -0.0268 ± 0.2913 | 0.1138 ± 0.2308 |
| CD3+CD4+; Week 8; n=34,37,34,37,28,27 | 0.0282 ± 0.1739 | 0.0539 ± 0.2996 | 0.0072 ± 0.2794 | -0.0287 ± 0.2054 | -0.0015 ± 0.2803 | 0.0778 ± 0.1826 |
| CD3+CD4+; Week 12; n= 35,37,32,34,27,27 | 0.0243 ± 0.2551 | 0.0957 ± 0.2713 | 0.1087 ± 0.2795 | 0.0216 ± 0.1929 | -0.0465 ± 0.3338 | 0.0181 ± 0.1872 |
| CD3+CD4+ treg flow cyto;Week 4;n=35,37,36,35,28,28 | 0.0117 ± 0.2048 | 0.0575 ± 0.2571 | 0.0825 ± 0.1875 | 0.0135 ± 0.2167 | -0.0229 ± 0.2878 | 0.1215 ± 0.2442 |
| CD3+CD4+ treg flow cyto;Week 8;n=31,35,32,36,27,25 | 0.0286 ± 0.1744 | 0.0687 ± 0.2923 | -0.0158 ± 0.2536 | -0.0284 ± 0.2018 | -0.0007 ± 0.2751 | 0.0849 ± 0.1883 |
| CD3+CD4+treg flow cyto;Week 12;n=32,36,31,32,25,24 | 0.0235 ± 0.2508 | 0.1058 ± 0.2718 | 0.0979 ± 0.2691 | 0.0141 ± 0.1885 | -0.0403 ± 0.3331 | 0.0213 ± 0.1940 |
| CD16+CD56+; Week 4; n=37,38,38,37,29,32 | -0.021 ± 0.0942 | -0.018 ± 0.0752 | -0.019 ± 0.0976 | -0.004 ± 0.1057 | -0.009 ± 0.0837 | 0.016 ± 0.0999 |
| CD16+CD56+; Week 8; n=34,37,34,37,28,27 | -0.013 ± 0.0909 | -0.012 ± 0.1594 | -0.016 ± 0.1045 | -0.009 ± 0.0919 | -0.029 ± 0.0860 | -0.012 ± 0.1131 |
| CD16+CD56+; Week 12; n= 35,37,32,34,27,27 | -0.038 ± 0.0884 | -0.021 ± 0.0911 | -0.022 ± 0.0792 | -0.036 ± 0.0702 | -0.039 ± 0.0909 | -0.020 ± 0.0888 |
| CD3+CD4+CD25+CD127; Week4;n=35,37,36,35,28,28 | 0.0006 ± 0.0139 | 0.0023 ± 0.0150 | 0.0022 ± 0.0172 | 0.0005 ± 0.0174 | -0.0050 ± 0.0179 | 0.0098 ± 0.0345 |
| CD3+CD4+CD25+CD127; Week8;n=31,35,32,36,27,25 | 0.0044 ± 0.0199 | 0.0062 ± 0.0167 | 0.0026 ± 0.0223 | 0.0029 ± 0.0196 | -0.0049 ± 0.0181 | 0.0054 ± 0.0222 |
| CD3+CD4+CD25+CD127; Week12;n=32,36,31,32,25,24 | 0.0050 ± 0.0193 | 0.0056 ± 0.0228 | 0.0081 ± 0.0229 | 0.0054 ± 0.0217 | 0.0007 ± 0.0230 | 0.0055 ± 0.0215 |
| CD3+CD4+foxP3+CD25+CD127;Week4;n=35,37,36,35,28,28 | 0.0009 ± 0.0125 | 0.0001 ± 0.0162 | 0.0009 ± 0.0129 | -0.0013 ± 0.0164 | 0.0008 ± 0.0099 | 0.0056 ± 0.0123 |
| CD3+CD4+foxP3+CD25+CD127;Week8;n=31,35,32,35,27,25 | 0.0070 ± 0.0184 | 0.0011 ± 0.0147 | 0.0021 ± 0.0182 | -0.0015 ± 0.0151 | 0.0032 ± 0.0151 | 0.0047 ± 0.0166 |
| CD3+CD4+foxP3+CD25+CD127Week12;n=32,36,31,32,25,24 | 0.0076 ± 0.0149 | 0.0003 ± 0.0198 | 0.0052 ± 0.0192 | -0.0012 ± 0.0180 | 0.0039 ± 0.0160 | 0.0059 ± 0.0127 |
| T &B cell NK lympho; Week4;n=37,38,38,37,29,32 | 0.009 ± 0.5461 | 0.101 ± 0.5287 | 0.092 ± 0.5122 | 0.021 ± 0.4664 | -0.082 ± 0.6206 | 0.228 ± 0.5116 |
| T &B cell NK lympho;Week8;n=34,37,34,37,28,27 | 0.059 ± 0.4430 | 0.083 ± 0.6737 | 0.025 ± 0.5688 | -0.070 ± 0.4141 | -0.109 ± 0.6219 | 0.132 ± 0.5150 |
| T &B cell NK lympho; Week12;n=35,37,32,34,27,27 | -0.041 ± 0.5922 | 0.174 ± 0.5825 | 0.140 ± 0.5609 | -0.009 ± 0.4041 | -0.236 ± 0.6830 | -0.001 ± 0.3842 |
Blood samples were collected from participants for evaluation of immunophenotyping parameters by Potential Clinical Importance Criteria at Baseline, Week 4, Week 8, Week 12 nd any visit post-screen. The immunophenotyping parameters included CD 19, CD3, CD3+CD8+, CD3+CD4+, CD16+CD56+, CD3+CD4+CD25+CD127, CD3+CD4+foxP3+CD25+CD127 and T and NK lympho. CD3, CD3+CD8+ and CD3+CD4+ were also evaluated by using treg flow cyto. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
| Participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| CD19; Baseline; n=40,41,43,40,41,40 | 0 | 0 | 5 | 2 | 1 | 2 |
| CD19; Week 4; n= 37,38,38,38,30,32 | 3 | 0 | 5 | 4 | 1 | 2 |
| CD19; Week 8; n= 34,37,34,38,29,27 | 2 | 1 | 3 | 4 | 3 | 2 |
| CD19; Week 12; n= 35,37,32,35,28,27 | 1 | 3 | 3 | 3 | 0 | 1 |
| CD19; post-screen; n= 38,39,38,39,30,32 | 4 | 3 | 7 | 7 | 3 | 4 |
| CD3; Baseline; n=40,41,43,41,41,40 | 8 | 3 | 6 | 1 | 4 | 3 |
| CD3; Week 4; n=37,38,38,38,30,32 | 6 | 3 | 6 | 2 | 4 | 1 |
| CD3; Week 8; n=34,37,34,38,29,27 | 5 | 3 | 5 | 2 | 2 | 4 |
| CD3; Week 12; n=35,37,32,35,28,27 | 4 | 2 | 5 | 1 | 2 | 2 |
| CD3; post-screen; n=38,39,38,39,30,32 | 8 | 5 | 9 | 4 | 6 | 7 |
| CD3 treg flow cyto;Baseline; n=38,40,42,39,40,37 | 0 | 0 | 0 | 0 | 0 | 0 |
| CD3 treg flow cyto; Week 4; n=37,38,37,37,30,30 | 0 | 0 | 0 | 0 | 0 | 0 |
| CD3 treg flow cyto; Week8; n=33,36,33,38,29,26 | 0 | 0 | 0 | 0 | 0 | 0 |
| CD3 treg flow cyto; Week 12; n= 34,37,32,34,27,25 | 0 | 0 | 1 | 0 | 0 | 0 |
| CD3treg flow cyto; postscreen; n=38,39,38,39,30,32 | 0 | 0 | 1 | 0 | 0 | 0 |
| CD3+CD8+; Baseline; n= 40,41,43,40,41,40 | 9 | 3 | 3 | 2 | 5 | 4 |
| CD3+CD8+; Week 4; n=37,38,38,38,30,32 | 5 | 3 | 4 | 3 | 3 | 3 |
| CD3+CD8+; Week 8; n=34,37,34,38,29,27 | 4 | 2 | 4 | 2 | 1 | 3 |
| CD3+CD8+; Week 12; n= 35,37,32,35,28,27 | 3 | 3 | 4 | 1 | 1 | 4 |
| CD3+CD8+; post-screen; n=38,39,38,39,30,32 | 8 | 4 | 8 | 4 | 5 | 6 |
| CD3+CD8+tregflowcyto;Baseline;n= 38,40,42,39,40,37 | 0 | 0 | 0 | 0 | 0 | 0 |
| CD3+CD8+tregflowcyto;Week4;n=37,38,37,37,30,30 | 0 | 0 | 0 | 0 | 0 | 0 |
| CD3+CD8+tregflowcyto;Week8;n=33,36,33,38,29,26 | 0 | 0 | 0 | 0 | 0 | 0 |
| CD3+CD8+tregflowcyto;Week12;n=34,37,32,34,27,25 | 0 | 0 | 1 | 0 | 0 | 0 |
| CD3+CD8+tregflowcytopostscreen;n=38,39,38,39,30,32 | 0 | 0 | 1 | 0 | 0 | 0 |
| CD3+CD4+; Baseline;n=40,41,43,40,41,40 | 8 | 5 | 6 | 3 | 4 | 2 |
| CD3+CD4+; Week 4; n=37,38,38,38,30,32 | 5 | 4 | 3 | 3 | 3 | 1 |
| CD3+CD4+; Week 8; n=34,37,34,38,29,27 | 4 | 6 | 3 | 5 | 6 | 3 |
| CD3+CD4+; Week 12; n= 35,37,32,35,28,27 | 5 | 6 | 5 | 2 | 7 | 4 |
| CD3+CD4+; post-screen;n=38,39,38,39,30,32 | 8 | 8 | 7 | 7 | 9 | 7 |
| CD3+CD4+tregflow cyto;Baseline;n=38,40,42,39,40,37 | 0 | 0 | 0 | 0 | 0 | 0 |
| CD3+CD4+tregflow cyto;Week4;n=37,38,37,37, 30,30 | 0 | 0 | 0 | 0 | 0 | 0 |
| CD3+CD4+tregflow cyto;Week8;n=33,36,33,38,29,26 | 0 | 0 | 0 | 0 | 0 | 0 |
| CD3+CD4+tregflow cyto;Week12;n=34,37,32,34,27,25 | 0 | 0 | 1 | 0 | 0 | 0 |
| CD3+CD4+tregflow;postscreen;n=38,39,38,39,30,32 | 0 | 0 | 1 | 0 | 0 | 0 |
| CD16+CD56+;Baseline;n=40,41,43,40,41,40 | 1 | 1 | 2 | 1 | 1 | 0 |
| CD16+CD56+;Week4;n=37,38,38,38,30,32 | 0 | 0 | 1 | 1 | 1 | 1 |
| CD16+CD56+;Week8;n=34,37,34,38,29,27 | 1 | 2 | 1 | 0 | 0 | 1 |
| CD16+CD56+;Week12;n=35,37,32,35,28,27 | 0 | 0 | 3 | 0 | 0 | 0 |
| CD16+CD56+;postscreen;n=38,39,38,39,30,32 | 1 | 2 | 3 | 1 | 1 | 1 |
| CD3+CD4+CD25+CD127;Baseline;n=38,40,42,39,40,37 | 0 | 0 | 0 | 0 | 0 | 0 |
| CD3+CD4+CD25+CD127;Week 4;n=37,38,37,37,30,30 | 3 | 2 | 1 | 3 | 4 | 1 |
| CD3+CD4+CD25+CD127;Week8;n=33,36,33,38,29,26 | 4 | 3 | 3 | 6 | 2 | 4 |
| CD3+CD4+CD25+CD127;Week12;n=34,37,32,34,27,25 | 4 | 4 | 6 | 6 | 5 | 5 |
| CD3+CD4+CD25+CD127;postscreen;n=38,39,38,39,30,32 | 7 | 6 | 8 | 9 | 9 | 7 |
| CD3+CD4+foxP3+CD25+CD127;Base;n=38,40,42,39,40,37 | 0 | 0 | 0 | 0 | 0 | 0 |
| CD3+CD4+foxP3+CD25+CD127;Week4;n=37,38,37,37,30,30 | 10 | 10 | 7 | 11 | 6 | 7 |
| CD3+CD4+foxP3+CD25+CD127;Week8;n=33,36,33,37,29,26 | 9 | 8 | 14 | 9 | 6 | 9 |
| CD3+CD4+foxP3+CD25+CD127;Week12;34,37,32,34,27,25 | 10 | 9 | 9 | 14 | 8 | 6 |
| CD3+CD4+foxP3+CD25+CD127;post;n=38,39,38,39,30,32 | 19 | 19 | 21 | 22 | 16 | 13 |
| T-B cell NK lympho;Baseline; n=40,41,43,40,41,40 | 1 | 1 | 2 | 0 | 0 | 1 |
| T-B cell NK lympho;Week4; n=37,38,38,38,30,32 | 0 | 1 | 0 | 0 | 2 | 0 |
| T-B cell NK lympho;Week8;n=34,37,34,38,29,27 | 0 | 1 | 1 | 2 | 0 | 0 |
| T-B cell NK lympho;Week12;n=35,37,32,35,28,27 | 0 | 0 | 1 | 0 | 3 | 0 |
| T-B cell NK lympho;postscreen;n=38,39,38,39,30,32 | 0 | 1 | 2 | 2 | 5 | 0 |
Blood samples were collected to evaluate change from Baseline in IgA, IgG, IM values at Baseline throughout the 12 weeks of study treatment. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
| G/L | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| IgA; Week 4; n= 37,38,38,38,30,32 | -0.016 ± 0.2528 | -0.103 ± 0.2108 | -0.079 ± 0.2003 | -0.026 ± 0.2342 | -0.046 ± 0.2179 | -0.045 ± 0.3141 |
| IgA; Week 8; n= 35,37,34,38,29,28 | -0.064 ± 0.2558 | -0.116 ± 0.2314 | -0.056 ± 0.2570 | 0.035 ± 0.2188 | 0.026 ± 0.2695 | -0.036 ± 0.3106 |
| IgA; Week 12; n= 36,37,32,35,28,27 | -0.056 ± 0.2820 | -0.099 ± 0.6148 | -0.140 ± 0.2207 | -0.042 ± 0.2657 | -0.038 ± 0.1744 | -0.016 ± 0.2462 |
| IgG; Week 4; n= 37,38,38,38,30,32 | -0.130 ± 1.0945 | -0.446 ± 0.8854 | -0.282 ± 1.2618 | -0.347 ± 1.1148 | -0.198 ± 1.2753 | -0.112 ± 1.1564 |
| IgG; Week 8; n= 35,37,34,38,29,28 | -0.007 ± 1.2785 | -0.457 ± 1.0787 | -0.121 ± 1.4233 | -0.200 ± 1.1449 | 0.428 ± 1.1984 | 0.203 ± 1.4037 |
| IgG; Week 12; n= 36,37,32,35,28,27 | -0.033 ± 1.2978 | -0.436 ± 3.8561 | -0.367 ± 1.0214 | -0.269 ± 0.9239 | 0.256 ± 1.5915 | 0.331 ± 0.8796 |
| IgM; Week 4; n=37,38,38,38,30,32 | -0.049 ± 0.1524 | -0.102 ± 0.1514 | -0.077 ± 0.0968 | -0.043 ± 0.1303 | -0.052 ± 0.0933 | -0.040 ± 0.0886 |
| IgM; Week 8; n= 35,37,34,38,29,28 | -0.070 ± 0.1069 | -0.095 ± 0.1314 | -0.111 ± 0.1290 | -0.052 ± 0.1167 | -0.014 ± 0.1396 | -0.040 ± 0.0956 |
| IgM; Week 12; n= 36,37,32,35,28,27 | -0.055 ± 0.1852 | -0.098 ± 0.1955 | -0.125 ± 0.1233 | -0.072 ± 0.1112 | -0.047 ± 0.1300 | -0.034 ± 0.0850 |
Blood samples were collected from participants for evaluation of immunoglobulin data outside the reference range at Baseline, Week 4, Week 8, Week 12 and any visit post-screen. The immunoglobulin parameters included IgA, IgG and Ig M. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
| Participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| IgA; Baseline; n= 40,41,43,41,42,40 | 2 | 3 | 2 | 1 | 4 | 2 |
| IgA; Week 4; n= 37,38,38,38,30,32 | 2 | 2 | 3 | 0 | 3 | 2 |
| IgA; Week 8; n= 35,37,34,38,29,28 | 2 | 1 | 3 | 2 | 1 | 2 |
| IgA; Week 12; n= 36,37,32,35,28,27 | 3 | 1 | 4 | 1 | 1 | 2 |
| IgA; post-screen; n= 38,39,38,39,30,32 | 4 | 3 | 4 | 2 | 3 | 3 |
| IgG; Baseline; n=40,41,43,41,42,40 | 2 | 5 | 1 | 4 | 3 | 3 |
| IgG; Week 4; n= 37,38,38,38,30,32 | 1 | 3 | 0 | 3 | 3 | 2 |
| IgG; Week 8; n=35,37,34,38,29,28 | 3 | 3 | 0 | 3 | 4 | 2 |
| IgG; Week 12; n=36,37,32,35,28,27 | 4 | 5 | 0 | 5 | 4 | 2 |
| IgG; post screen; n= 38,39,38,39,30,32 | 4 | 6 | 0 | 5 | 6 | 3 |
| IgM;Baseline; n= 40,41,43,41,42,40 | 4 | 7 | 3 | 3 | 6 | 4 |
| IgM; Week 4; n=37,38,38,38,30,32 | 3 | 5 | 6 | 1 | 2 | 6 |
| IgM; Week 8; n= 35,37,34,38,29,28 | 3 | 4 | 7 | 3 | 3 | 5 |
| IgM; Week12; n= 36,37,32,35,28,27 | 4 | 5 | 7 | 2 | 3 | 6 |
| IgM; post-screen; n=38,39,38,39,30,32 | 4 | 5 | 10 | 4 | 3 | 6 |
SBP and DBP were measured from Baseline up to follow up Visit 1 at Week 14 in semi-supine position after at least 5 minutes of rest. The Baseline value was taken at Day 1 and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
| Millimeter of mercury (mmHg) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| SBP; Week 1; n= 38,31,39,37,38,33 | -1.6 ± 8.89 | -2.3 ± 11.02 | -2.3 ± 14.72 | -1.9 ± 9.77 | 0.8 ± 9.32 | -0.7 ± 9.45 |
| SBP; Week 2; n=39,39,39,39,33,32 | -1.7 ± 12.22 | 0.6 ± 10.57 | -4.3 ± 13.37 | -1.2 ± 11.41 | -0.8 ± 10.41 | -1.6 ± 6.90 |
| SBP; Week 4; n= 38,39,38,39,30,32 | -1.7 ± 10.57 | 0.5 ± 10.00 | -3.8 ± 9.05 | -1.8 ± 11.94 | 1.9 ± 13.33 | -0.5 ± 14.24 |
| SBP; Week 8; n= 36,37,34,38,29,28 | -1.9 ± 10.74 | -0.5 ± 11.27 | -4.3 ± 11.38 | -1.9 ± 9.86 | 0.0 ± 11.29 | 1.0 ± 17.08 |
| SBP; Week 12; n= 36,37,32,35,28,28 | -3.1 ± 10.28 | -0.1 ± 11.64 | -1.9 ± 12.62 | -2.4 ± 10.71 | -0.5 ± 10.44 | -0.5 ± 12.67 |
| SBP; Week 14; n=34,35,32,34,31,29 | -1.0 ± 11.95 | -0.5 ± 12.52 | -1.4 ± 12.76 | -1.9 ± 9.46 | 1.2 ± 13.18 | 0.3 ± 11.29 |
| SBP; EW; n= 3,4,7,3,11,11 | 5.3 ± 8.08 | -5.3 ± 18.01 | 4.9 ± 13.63 | -0.7 ± 7.37 | 1.2 ± 8.81 | 2.0 ± 6.96 |
| DBP; Week 1; n=38,31,39,37,38,33 | -2.0 ± 8.55 | 1.4 ± 8.48 | -1.9 ± 8.74 | -1.5 ± 7.33 | 1.1 ± 9.29 | -0.4 ± 7.53 |
| DBP; Week 2; n=39,39,39,39,33,32 | -3.4 ± 9.60 | 0.1 ± 8.14 | -3.7 ± 7.63 | -3.3 ± 7.07 | -2.2 ± 10.29 | -0.9 ± 5.97 |
| DBP; Week 4; n=38,39,38,39,30,32 | -3.0 ± 12.21 | 0.9 ± 7.98 | -3.1 ± 9.31 | -4.0 ± 7.98 | -0.1 ± 10.49 | 1.9 ± 9.18 |
| DBP; Week 8; n=36,37,34,38,29,28 | -4.8 ± 9.79 | 1.0 ± 8.07 | -3.3 ± 9.24 | -2.1 ± 8.91 | -0.2 ± 10.10 | 2.2 ± 10.08 |
| DBP; Week 12; n= 36,37,32,35,28,28 | -6.5 ± 8.86 | 2.6 ± 7.02 | -2.8 ± 8.82 | -4.0 ± 9.18 | 0.9 ± 9.81 | 1.3 ± 8.93 |
| DBP; Week 14; n= 34,35,32,34,31,29 | -5.6 ± 9.23 | -0.5 ± 7.71 | -2.9 ± 9.10 | -0.4 ± 8.49 | -0.4 ± 9.45 | 0.9 ± 7.75 |
| DBP; EW; n= 3,4,7,3,11,11 | 3.3 ± 3.06 | 1.3 ± 3.40 | 0.0 ± 10.82 | -1.0 ± 9.54 | 2.3 ± 3.66 | -2.7 ± 7.02 |
Pulse rate were measured from Baseline up to follow up Visit 1 at Week 14 in semi-supine position after at least 5 minutes of rest. The Baseline value was taken at Day 1 and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
| Beats per minute (bpm) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1; n= 38,41,39,37,38,33 | 5.8 ± 9.19 | 2.5 ± 8.68 | 0.8 ± 10.19 | -0.4 ± 9.39 | 0.4 ± 9.43 | -0.4 ± 9.82 |
| Week 2; n= 39,39,39,39,33,32 | 3.7 ± 10.67 | 2.3 ± 10.90 | 0.1 ± 9.63 | 1.0 ± 10.90 | 1.5 ± 11.99 | 1.0 ± 10.47 |
| Week 4; n= 38,39,38,39,30,32 | 6.2 ± 10.02 | 0.6 ± 10.79 | -0.3 ± 12.30 | 0.4 ± 10.88 | -1.7 ± 11.67 | 0.1 ± 8.42 |
| Week 8; n= 36,37,34,38,29,28 | 4.1 ± 9.72 | 0.6 ± 10.27 | -1.7 ± 9.59 | 3.2 ± 11.23 | -0.2 ± 11.45 | 0.8 ± 8.97 |
| Week 12; n= 36,37,32,35,28,28 | 3.0 ± 10.03 | -0.0 ± 11.55 | 0.0 ± 10.08 | 0.4 ± 9.74 | -1.9 ± 9.58 | 1.3 ± 10.76 |
| Week 14; n= 34,35,32,34,31,29 | 3.3 ± 9.38 | 3.5 ± 11.65 | 0.6 ± 10.00 | 2.5 ± 10.97 | 0.8 ± 11.06 | 0.7 ± 8.56 |
| EW; n= 3,4,7,3,11,11 | -13.7 ± 1.15 | 0.3 ± 3.50 | -6.0 ± 9.83 | -2.7 ± 8.96 | 4.2 ± 12.18 | -0.5 ± 9.15 |
Temperature were measured from Baseline up to follow up Visit 1 at Week 14 in semi-supine position after at least 5 minutes of rest. The Baseline value was taken at Day 1 and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.
| Degree Celsius | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1; n= 38,41,39, 37,38,33 | 0.013 ± 0.3640 | -0.056 ± 0.2618 | 0.015 ± 0.3689 | -0.006 ± 0.3932 | -0.053 ± 0.7928 | -0.024 ± 0.2693 |
| Week 2; n=39,39,39,39,32,32 | -0.054 ± 0.4973 | -0.064 ± 0.2680 | 0.005 ± 0.3332 | -0.069 ± 0.4691 | -0.097 ± 0.7082 | 0.016 ± 0.2841 |
| Week 4; n= 38,39,38,39,30,32 | -0.074 ± 0.4428 | -0.023 ± 0.3256 | -0.013 ± 0.3458 | -0.068 ± 0.4902 | -0.030 ± 0.6706 | 0.013 ± 0.2459 |
| Week 8; n= 36,37,34,38,29,28 | 0.006 ± 0.4276 | -0.024 ± 0.2671 | -0.056 ± 0.3295 | 0.045 ± 0.4011 | 0.062 ± 0.7566 | 0.021 ± 0.3304 |
| Week 12; n=36,37,32,35,28,28 | 0.003 ± 0.4212 | -0.068 ± 0.3292 | -0.078 ± 0.2814 | -0.040 ± 0.4532 | 0.043 ± 0.7618 | 0.004 ± 0.4574 |
| Week 14;n=34,35,32,34,31,29 | -0.079 ± 0.4059 | -0.131 ± 0.6416 | -0.059 ± 0.3618 | -0.109 ± 0.4876 | -0.013 ± 0.8740 | -0.052 ± 0.3582 |
| EW; n= 3,4,7,3,11,11 | -0.033 ± 0.1528 | 0.000 ± 0.3651 | 0.100 ± 0.2517 | 0.400 ± 0.5568 | -0.182 ± 0.5212 | 0.164 ± 0.4985 |
Blood samples were collected from participants for evaluation of vital signs by Potential Clinical Importance Criteria from Baseline to Week 14, EW and any visit post-screen. The vital signs included SBP, DBP and pulse rate. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
| Participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| SBP; Baseline; n= 40,41,43,41,42,40 | 0 | 0 | 0 | 0 | 0 | 1 |
| SBP; Week 1; n= 38,41,39,37,38,33 | 1 | 1 | 0 | 0 | 0 | 0 |
| SBP; Week 2; n= 39,39,39,39,33,32 | 0 | 0 | 0 | 2 | 0 | 1 |
| SBP; Week 4; n= 38,39,38,39,30,32 | 0 | 0 | 0 | 1 | 0 | 1 |
| SBP; Week 8; n= 36,37,34,38,29,28 | 0 | 0 | 0 | 0 | 0 | 2 |
| SBP; Week 12; n= 36,37,32,35,28,28 | 0 | 1 | 1 | 1 | 0 | 1 |
| SBP: Week 14; n= 34,35,32,34,31,29 | 0 | 0 | 0 | 2 | 0 | 1 |
| SBP; EW; n= 3,4,7,3,11,11 | 0 | 0 | 0 | 0 | 0 | 0 |
| SBP; post-screen; n= 40,41,43,41,42,40 | 1 | 2 | 1 | 3 | 0 | 3 |
| DBP; Baseline; n= 40,41,43,41,42,40 | 0 | 0 | 1 | 0 | 0 | 0 |
| DBP; Week 1; n=38,41,39,37,38,33 | 0 | 0 | 0 | 0 | 0 | 0 |
| DBP; Week 2; n=39,39,39,39,33,32 | 0 | 0 | 0 | 0 | 1 | 0 |
| DBP; Week 4; n=38,39,38,39,30,32 | 0 | 0 | 0 | 0 | 0 | 1 |
| DBP; Week 8; n= 36,37,34,38,29,28 | 0 | 0 | 0 | 1 | 1 | 1 |
| DBP; Week 12; n= 36,37,32,35,28,28 | 0 | 0 | 0 | 1 | 1 | 0 |
| DBP; Week 14; n= 34,35,32,34,31,29 | 0 | 0 | 0 | 1 | 0 | 0 |
| DBP; EW; n= 3,4,7,3,11,11 | 1 | 0 | 0 | 0 | 0 | 0 |
| DBP; post-screen; n= 40,41,43,41,42,40 | 1 | 0 | 1 | 1 | 1 | 2 |
| Pulse rate; Baseline; n= 40,41,43,41,42,40 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pulse rate; Week 1; n= 38,41,39,37,38,33 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pulse rate;Week 2; n= 39,39,39,39,33,32 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pulse rate; Week 4; n= 38,39,38,39,30,32 | 0 | 0 | 0 | 1 | 0 | 0 |
| Pulse rate; Week 8; n= 36,37,34,38,29,28 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pulse rate; Week 12; n= 36,37,32,35,28,28 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pulse rate; Week 14; n= 34,35,32,34,31,29 | 0 | 1 | 1 | 0 | 0 | 0 |
| Pulse rate; EW; n= 3,4,7,3,11,11 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pulse rate; post-screen; n=40,41,43,41,42,40 | 0 | 1 | 1 | 1 | 0 | 0 |
Single measurements of 12-lead ECGs were obtained at Baseline , Week 1, Week 12, Week 14 (follow up 1), EW and at any time post-screen using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (QTc). Baseline was defined as the latest assessment prior to the first dose. For multiple ECGs at one visit, or "Any visit post-screen", a participant was categorized as "Abnormal" if \>=1 assessment was abnormal. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Baseline; n= 40,41,43,41,42,40 | 8 | 6 | 4 | 5 | 5 | 5 |
| Week 1; n= 37,41,39,37,38,33 | 8 | 8 | 4 | 5 | 5 | 6 |
| Week 12; n= 36,37,32,35,28,28 | 7 | 6 | 4 | 3 | 1 | 4 |
| Week 14; n= 34,34,32,34,31,29 | 8 | 4 | 5 | 6 | 1 | 5 |
| EW; n= 3,3,7,3,10,11 | 0 | 1 | 0 | 2 | 0 | 1 |
| post-screen; n= 40,41,41,39,41,40 | 12 | 10 | 5 | 8 | 5 | 9 |
Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of the study treatment until the Folow up Visit 2 at Week 16.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK2894512 1% Cream Twice Daily | 0/40 (0%) | 1/40 (2.5%) | 28/40 (70%) |
| GSK2894512 1% Cream Once Daily | 0/41 (0%) | 0/41 (0%) | 22/41 (53.7%) |
| GSK2894512 0.5% Cream Twice Daily | 0/43 (0%) | 0/43 (0%) | 20/43 (46.5%) |
| GSK2894512 0.5% Cream Once Daily | 0/41 (0%) | 0/41 (0%) | 23/41 (56.1%) |
| Vehicle Cream Twice Daily | 0/42 (0%) | 0/42 (0%) | 19/42 (45.2%) |
| Vehicle Cream Once Daily | 0/40 (0%) | 0/40 (0%) | 15/40 (37.5%) |
| Event | GSK2894512 1% Cream Twice Daily | GSK2894512 1% Cream Once Daily | GSK2894512 0.5% Cream Twice Daily | GSK2894512 0.5% Cream Once Daily | Vehicle Cream Twice Daily | Vehicle Cream Once Daily |
|---|---|---|---|---|---|---|
| AnxietyPsychiatric disorders | 1/40 | 0/41 | 0/43 | 0/41 | 0/42 | 0/40 |
| Attention deficit /hyperactivity disorderPsychiatric disorders | 1/40 | 0/41 | 0/43 | 0/41 | 0/42 | 0/40 |
| Event | GSK2894512 1% Cream Twice Daily | GSK2894512 1% Cream Once Daily | GSK2894512 0.5% Cream Twice Daily | GSK2894512 0.5% Cream Once Daily | Vehicle Cream Twice Daily | Vehicle Cream Once Daily |
|---|---|---|---|---|---|---|
| FolliculitisInfections and infestations | 4/40 | 8/41 | 3/43 | 3/41 | 0/42 | 0/40 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 2/40 | 0/41 | 3/43 | 1/41 | 4/42 | 5/40 |
| NasopharyngitisInfections and infestations | 3/40 | 5/41 | 4/43 | 1/41 | 4/42 | 3/40 |
| Upper respiratoryInfections and infestations | 4/40 | 2/41 | 3/43 | 2/41 | 3/42 | 1/40 |
| HeadacheNervous system disorders | 4/40 | 1/41 | 1/43 | 3/41 | 0/42 | 2/40 |
| ImpetigoInfections and infestations | 1/40 | 0/41 | 0/43 | 0/41 | 0/42 | 3/40 |
| AcneSkin and subcutaneous tissue disorders | 2/40 | 0/41 | 1/43 | 3/41 | 1/42 | 0/40 |
| DiarrhoeaGastrointestinal disorders | 1/40 | 1/41 | 0/43 | 2/41 | 0/42 | 0/40 |
| Application site painGeneral disorders | 1/40 | 0/41 | 1/43 | 0/41 | 2/42 | 1/40 |
| BronchitisInfections and infestations | 0/40 | 0/41 | 2/43 | 0/41 | 0/42 | 0/40 |
| Age, Continuous(Years) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD | Total |
|---|---|---|---|---|---|---|---|
| Mean | 28.5 ± 13.90 | 31.6 ± 15.72 | 29.0 ± 15.91 | 29.3 ± 14.02 | 27.9 ± 14.72 | 29.4 ± 15.15 | 29.3 ± 14.83 |
| Sex: Female, Male(Participants) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD | Total |
|---|---|---|---|---|---|---|---|
| Female | 18 | 24 | 17 | 22 | 23 | 17 | 121 |
| Male | 22 | 17 | 26 | 19 | 19 | 23 | 126 |
| Race/Ethnicity, Customized(Participants) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD | Total |
|---|---|---|---|---|---|---|---|
| Race/Ethnicity, Customized — White/Caucasian | 16 | 18 | 17 | 17 | 20 | 12 | 100 |
| Race/Ethnicity, Customized — Black/African American | 7 | 10 | 11 | 12 | 6 | 12 | 58 |
| Race/Ethnicity, Customized — American Indian/Alaska Native | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Race/Ethnicity, Customized — Asian/S.E. Asian Descent/Japanese | 15 | 13 | 13 | 10 | 15 | 14 | 80 |
| Race/Ethnicity, Customized — American Indian/Alaska Native and African American | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Race/Ethnicity, Customized — Asian/S.E. Asian/Japanese and African American | 1 | 0 | 1 | 0 | 0 | 0 | 2 |
| Race/Ethnicity, Customized — Asian/S.E. Asian/Japanese and Black and White | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized — Asian/S.E. Asian/Japanese and White/Caucasian | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized — Black/African American and White/Caucasian | 1 | 0 | 0 | 0 | 1 | 1 | 3 |
The record gives a start of Dec 2015, a primary completion of Jan 2017 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2017, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tapinarof